[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

USRE49698E1 - Substituted dihydroquinazolines - Google Patents

Substituted dihydroquinazolines Download PDF

Info

Publication number
USRE49698E1
USRE49698E1 US16/934,363 US202016934363A USRE49698E US RE49698 E1 USRE49698 E1 US RE49698E1 US 202016934363 A US202016934363 A US 202016934363A US RE49698 E USRE49698 E US RE49698E
Authority
US
United States
Prior art keywords
alkyl
trifluoromethyl
represents hydrogen
cyano
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US16/934,363
Inventor
Tobias Wunberg
Judith Baumeister
Ulrich Betz
Mario Jeske
Thomas Lampe
Susanne Nikolic
Jurgen Reefschlager
Rudolf Schohe-Loop
Frank Sussmeier
Holger Zimmermann
Rolf Grosser
Kerstin Henninger
Guy Hewlett
Jorg Keldenich
Dieter Lang
Peter Nell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AIC246 AG and Co KG
Original Assignee
AIC246 AG and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AIC246 AG and Co KG filed Critical AIC246 AG and Co KG
Priority to US16/934,363 priority Critical patent/USRE49698E1/en
Assigned to AIC246 GMBH & CO. KG reassignment AIC246 GMBH & CO. KG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AICURIS ANTI-INFECTIVE CURES GMBH
Assigned to AIC246 AG & CO. KG reassignment AIC246 AG & CO. KG CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: AIC246 GMBH & CO. KG
Application granted granted Critical
Publication of USRE49698E1 publication Critical patent/USRE49698E1/en
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Definitions

  • Reissue application Ser. No. 15/955,254 is a continuation of Reissue application Ser. No. 14/682,512 and an application for reissue of application Ser. No. 10/832,109 (U.S. Pat. No. 7,196,086).
  • Reissue application Ser. No. 14/682,512 is an application for reissue of application Ser. No. 10/832,109 (U.S. Pat. No. 7,196,086).
  • Reissue application Ser. No. 14/682,512 matured into Reissue U.S. Pat. No. RE46,791 on Apr. 17, 2018.
  • the invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
  • One object of the present invention is therefore to provide novel compounds having the same or improved antiviral effect for the treatment of viral infective diseases in humans and animals.
  • the present invention provides compounds of the formula
  • Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts, compounds mentioned below as embodiment(s) and their salts, solvates and solvates of the salts, unless the compounds below, embraced by formula (I), are already salts, solvates and solvates of the salts.
  • the compounds according to the invention may, depending on their structure, exist in stereoisomeric forms (enantiomers, diastereomers).
  • the invention therefore relates to the enantiomers or diastereomers and respective mixtures thereof.
  • the stereoisomerically pure constituents can be isolated in a known manner from such mixtures of enantiomers and/or diastereomers.
  • the compounds according to the invention may exist in tautomeric forms, the present invention embraces all such tautomeric forms.
  • Salts which are preferred for the purposes of the present invention are physiologically acceptable salts of the compounds according to the invention.
  • the invention also embraces salts which are per se not suitable for pharmaceutical applications but can be used, for example, for isolating or purifying the compounds according to the invention.
  • Physiologically acceptable salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulphonic acids, for example salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • hydrochloric acid hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid,
  • Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and preferably, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, such as, by way of example and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine.
  • customary bases such as, by way of example and preferably, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example calcium and magnesium salts) and ammoni
  • Solvates refer for the purposes of the invention to those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates in which the coordination takes place with water.
  • Alkyl per se and “alk” and “alkyl” in alkoxy, alkylamino, alkylcarbonyl, alkylsulphonyl, alkylaminosulphonyl and alkoxycarbonyl are a straight-chain or branched alkyl radical having generally 1 to 6, preferably 1 to 4, particularly preferably 1 to 3, carbon atoms, by way of example and preferably methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.
  • Alkoxy is, by way of example and preferably, methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
  • Alkylamino is an alkylamino radical having one or two alkyl substituents (chosen independently of one another), by way of example and preferably methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n-hexylamino, N,N-dimethylamino, N,N-diethylamino, N-ethyl-N-methylamino, N-methyl-N-n-propylamino, N-isopropyl-N-n-propyl-amino, N-tert-butyl-N-methylamino, N-ethyl-N-n-pentylamino and N-n-hexyl-N-methylamino.
  • C 1 —C 3 -alkylamino is, for example, a monoalkylamino radical having 1 to 3 carbon
  • Alkylsulphonyl is, by way of example and preferably, methylsulphonyl, ethylsulphonyl, n-propyl-sulphonyl, iso-propylsulphonyl, tert-butylsulphonyl, n-pentylsulphonyl and n-hexylsulphonyl.
  • Alkylaminosulphonyl is an alkylaminosulphonyl radical having one or two alkyl substituents (chosen independently of one another), by way of example and preferably methylaminosulphonyl, ethylaminosulphonyl, n-propylaminosulphonyl, isopropylaminosulphonyl, tert-butylaminosulphonyl, n-pentylaminosulphonyl, n-hexyl-aminosulphonyl, N-N-dimethylaminosulphonyl, N-N-diethyl-aminosulphonyl, N-ethyl-N-methylaminosulphonyl, N-methyl-N-n-propylamiinosulphonyl N-methyl-N-n-propylaminosulphonyl, N-isopropyl-N-n-propyl-aminosulphonyl, N-tert-butyl-N-methyl
  • C 1 —C 3 -alkylaminosulphonyl is, for example, a monoalkylaminosulphonyl radical having 1 to 3 carbon atoms or a dialkylaminosulphonyl radical having in each case 1 to 3 carbon atoms per alkyl substituent.
  • Alkylcarbonyl is, by way of example and preferably, acetyl and propanoyl.
  • Alkoxycarbonyl is, by way of example and preferably, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, iso-propoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxy-carbonyl.
  • Aryl is a mono- to tricyclic aromatic carbocyclic radical having generally 6 to 14 carbon atoms; by way of example and preferably phenyl, naphthyl and phenanthrenyl.
  • Halogen is fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine.
  • a symbol * on a carbon atoms means that the compound, with respect to the configuration at this carbon atom, is present in enantiomerically pure form which, for the purposes of the present invention, is to be understood as meaning an enantiomeric excess of more than 90% (>90% ee).
  • R 3 represents trifluoromethyl, chlorine, methyl, isopropyl or tert-butyl.
  • R 1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring
  • R 3 represents trifluoromethyl, chlorine or methyl
  • R 3 is attached to the phenyl ring via the position meta to the point of attachment of the phenyl ring, which position is opposite to that of R 1 .
  • R 1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring
  • R 3 represents trifluoromethyl
  • R 3 is attached to the phenyl ring via the position meta to the point of attachment of the phenyl ring, which position is opposite to that of R 1 .
  • radical definitions given in the respective combinations or preferred combinations of radicals are, independently of the combinations of radicals given in each case, also replaced by radical definitions of other combinations.
  • the invention furthermore provides a process for preparing the compounds of the formula (I), which comprises reacting compounds of the formula
  • the reaction is generally carried out using bases in inert solvents, preferably in a temperature range of from room temperature to the reflux temperature of the solvent, at atmospheric pressure.
  • Suitable bases are, for example, alkali metal hydroxides, such as sodium hydroxide, lithium hydroxide or potassium hydroxide, or alkali metal carbonates, such as caesium carbonate, sodium carbonate or potassium carbonate, if appropriate in aqueous solution; preference is given to sodium hydroxide in water.
  • alkali metal hydroxides such as sodium hydroxide, lithium hydroxide or potassium hydroxide
  • alkali metal carbonates such as caesium carbonate, sodium carbonate or potassium carbonate
  • Inert solvents are, for example, ethers, such as 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols, such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, or mixtures of solvents; preference is given to dioxane or tetrahydrofuran.
  • ethers such as 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether
  • alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, or mixtures of solvents; preference is given to dioxane or tetrahydrofuran.
  • reaction is generally carried out using acids in inert solvents, preferably in a temperature range of from 0° C. to 40° C., at atmospheric pressure.
  • suitable acids are hydrogen chloride in dioxane, hydrogen bromide in acetic acid or trifluoroacetic acid in methylene chloride.
  • Both steps of the reaction are generally carried out in inert solvents, preferably in a temperature range of from room temperature to 100° C., at atmospheric pressure.
  • silica gel is added to the reaction mixture.
  • the reaction is preferably carried out with work-up between the first and the second step.
  • Suitable inert solvents are, for example, halogenated hydrocarbons, such as methylene chloride, trichloromethane, carbon tetrachloride, trichloroethane, tetrachloroethane, 1,2-dichloroethane or trichloroethylene, ethers, such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents, such as dimethylformamide, dimethylacetamide, acetonitrile or ethyl acetate, or mixtures of solvents; preference is given to methylene chloride.
  • halogenated hydrocarbons such as methylene
  • the compounds of the formula (IV) are known or can be synthesized by known processes from the corresponding starting materials.
  • the compounds of the formula (V) are known or can be synthesized by known processes from the corresponding starting materials, for example by a Buchwald-Hartwig reaction according to the synthesis scheme below (review in: C. G. Frost, P. Mendonca, J. Chem. Soc., Perkin Trans I, 1998, 2615-2623):
  • the starting materials required for this purpose are known or can be synthesized by known processes from the corresponding starting materials.
  • the reaction is generally carried out in inert solvents, in the presence of a base, preferably in a temperature range of from room temperature to 50° C., at atmospheric pressure.
  • Suitable inert solvents are, for example, ethers, such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents, such as dimethylformamide, dimethylacetamide, acetonitrile or pyridine; preference is given to acetonitrile.
  • ethers such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether
  • hydrocarbons such as benzene, xylene, toluene, hexane,
  • Suitable bases are, for example, alkali metal and alkaline earth metal carbonates, such as caesium carbonate, sodium carbonate or potassium carbonate, or amines, such as triethylamine, diisopropylethylamine, N-methylmorpholine or pyridine; preference is given to triethylamine.
  • alkali metal and alkaline earth metal carbonates such as caesium carbonate, sodium carbonate or potassium carbonate
  • amines such as triethylamine, diisopropylethylamine, N-methylmorpholine or pyridine; preference is given to triethylamine.
  • the compounds of the formula (VI) are known or can be synthesized by known processes from the corresponding starting materials, for example by a Heck reaction or a Wittig-Homer Wittig-Horner reaction, according to the synthesis schemes below:
  • the starting materials required for this purpose are known or can be synthesized by known processes from the corresponding starting materials.
  • the compounds of the general formula (I) according to the invention show a surprising range of effects which could not have been predicted. They show an antiviral effect on representatives of the group of the Herpes viridae (Herpes viruses), especially on cytomegalo viruses (CMV), in particular, on human cytomegalovirus (HCMV).
  • Herpes viruses Herpes viridae
  • CMV cytomegalo viruses
  • HCMV human cytomegalovirus
  • the present invention further provides the use of the compounds according to the invention for the treatment and/or prophylaxis of diseases, especially of infections with viruses, in particular the viruses mentioned above, and the infective diseases caused by these infections.
  • a viral infection is to be understood as including both an infection with a virus and a disease caused by an infection with a virus.
  • the present invention also provides the use of the compounds according to the invention for the treatment and/or prophylaxis of disorders, in particular the disorders mentioned above.
  • the present invention also provides the use of the compounds according to the invention for preparing a medicament for the treatment and/or prophylaxis of disorders, in particular the disorders mentioned above.
  • the compounds according to the invention are preferably used for preparing medicaments suitable for the prophylaxis and/or treatment of infections with a representative of the group of the Herpes viridae, in particular a cytomegalovirus, in particular the human cytomegalovirus.
  • the present invention also provides a method for the treatment and/or prophylaxis of disorders, in particular the disorders mentioned above, using an antivirally effective amount of the compounds according to the invention.
  • the present invention also provides medicaments comprising at least one compound according to the invention and at least one or more further active compounds, in particular for the treatment and/or prophylaxis of the disorders mentioned above.
  • Active compounds suitable for combinations are, by way of example and preferably: antiviral active compounds, such as gancyclovir or acyclovir.
  • the compounds according to the invention can act systemically and/or locally.
  • they can be administered in a suitable way, such as, for example, by the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival or otic route, or as implant or stent.
  • Suitable for oral administration are known administration forms which deliver the compounds according to the invention rapidly and/or in modified form and which comprise the compounds according to the invention in crystalline and/or amorphous and/or dissolved form, such as, for example, tablets (uncoated or coated tablets, for example tablets provided with enteric coatings or coatings which dissolve slowly or are insoluble and which control the release of the compound according to the invention), tablets which disintegrate rapidly in the oral cavity and/or films/wafers, films/lyophylisates, capsules (for example Hart or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
  • tablets uncoated or coated tablets, for example tablets provided with enteric coatings or coatings which dissolve slowly or are insoluble and which control the release of the compound according to the invention
  • tablets which disintegrate rapidly in the oral cavity and/or films/wafers, films/lyophylisates capsules (for example Hart or soft gelatin capsule
  • Parenteral administration can take place with avoidance of an adsorption step (for example intravenously, intraarterially, intracardially, intraspinally or intralumbally) or with inclusion of absorption (for example intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally).
  • Administration forms suitable for parenteral administration are, inter alia, preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • Examples suitable for other administration routes are, for example, pharmaceutical forms for inhalation (inter alia powder inhalers, nebulizers), nasal drops/solutions/sprays; tablets to be administered lingually, sublingually or buccally, films/wafers or capsules, suppositories, preparations for the eyes or ears, vaginal capsules, aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems, milk, pastes, foams, dusting powders, implants or stents.
  • pharmaceutical forms for inhalation inter alia powder inhalers, nebulizers
  • nasal drops/solutions/sprays tablets to be administered lingually, sublingually or buccally, films/wafers or capsules, suppositories, preparations for the eyes or ears, vaginal capsules, aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions, ointments, cream
  • the compounds according to the invention can be converted into the stated administration forms.
  • auxiliaries include, inter alia, carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecyl sulphate, polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (for example antioxidants such as ascorbic acid), colorants (for example inorganic pigments such as iron oxides) and flavour- and/or odour-masking agents.
  • carriers for example microcrystalline cellulose, lactose, mannitol
  • solvents for example liquid polyethylene glycols
  • emulsifiers and dispersants or wetting agents for example sodium dodecyl sulphate, polyoxysorbitan oleate
  • binders for example polyvinylpyrrolidone
  • synthetic and natural polymers for example albumin
  • stabilizers
  • the present invention furthermore provides medicaments comprising at least one compound according to the invention, usually together with one or more inert, non-toxic, pharmaceutically acceptable auxiliaries, and their use for the purposes mentioned above.
  • intravenous administration amounts of about 0.001 to 10 mg/kg, preferably about 0.01 to 5 mg/kg, of body weight to achieve effective results, and the dosage on oral administration is about 0.01 to 25 mg/kg, preferably 0.1 to 10 mg/kg, of body weight.
  • Method 1 (analytical HPLC): column: Kromasil C18 60 mm ⁇ 2 mm; temperature: 30° C.; flow rate: 0.75 ml/min; mobile phase A: 0.005 M HClO 4 , mobile phase B: acetonitrile; gradient: ⁇ 0.5 min 98% A, ⁇ 4.5 min 10% A, ⁇ 6.5 min 10% A.
  • Method 2 (preparative HPLC): column: GromSil C18, 250 mm ⁇ 30 mm; flow rate: 50 ml/min; time per run: 38 min; detection: 210 nm; mobile phase A: water, mobile phase B: acetonitrile; gradient: 10% B (3 min)->90% B (31 min)->90% B (34 min)->10% B (34.01 min).
  • Method 3 column: GromSil 120 ODS-4 HE, 50 mm ⁇ 2.0 mm, 3 ⁇ m; mobile phase A: 1 l of water+1 ml of 50% strength formic acid, mobile phase B: 1 l of acetonitrile+1 ml of 50% strength formic acid; gradient: 0.0 min 100% A ⁇ 0.2 min 100% A ⁇ 2.9 min 30% A ⁇ 3.1 min 10% A ⁇ 4.5 min 10% A; oven: 55° C.; flow rate: 0.8 ml/min; UV detection: 208-400 nm.
  • Method 4 (preparative HPLC, separation of enantiomers, carboxylic acids): column: packing chiral silica gel selector KBD 8361 (420 mm ⁇ 100 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide) poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether; flow rate: 100 ml/min; the compound is dissolved in methyl tert-butyl ether/ethyl acetate (9:1).
  • Method 5 (preparative HPLC): column: GromSil C18, 250 mm ⁇ 30 mm; flow rate: 50 ml/min; time per run: 38 min; detection: 210 nm; mobile phase A: water with 0.1% formic acid, mobile phase B: acetonitrile; gradient: 10% B (3 min)->90% B (31 min)->90% B (34 min)->10% B (34.01 min).
  • Method 6 (analytical HPLC): instrument: HP 1100 with DAD detection; column: Kromasil RP-18, 60 mm ⁇ 2 mm, 3.5 ⁇ m; mobile phase A: 5 ml of HClO 4 /l of water, mobile phase B: acetonitrile; gradient: 0 min 2% B, 0.5 min 2% B, 4.5 min 90% B, 9 min 90% B; flow rate: 0.75 ml/min; temp.: 30° C.; detection: UV 210 nm.
  • Method 7 instrument: Micromass Platform LCZ with HPLC Agilent series 1100; column: GromSIL120 ODS-4 HE, 50 mm ⁇ 2.0 mm, 3 ⁇ m; mobile phase A: 1 l of water+1 ml of 50% strength formic acid, mobile phase B: 1 l of acetonitrile+1 ml of 50% strength formic acid; gradient: 0.0 min 100% A ⁇ 0.2 min 100% A ⁇ 2.9 min 30% A ⁇ 3.1 min 10% A ⁇ 4.5 min 10% A; oven: 55° C.; flow rate: 0.8 ml/min; UV detection: 210 nm.
  • Method 8 instrument: Micromass Platform LCZ, HP 1100; column: Symmetry C18, 50 mm ⁇ 2.1 mm, 3.5 ⁇ m; mobile phase A: acetonitrile+0.1% formic acid, mobile phase B: water+0.1% formic acid; gradient: 0.0 min 10% A ⁇ 4.0 min 90% A ⁇ 6.0 min 90% A; oven: 40° C.; flow rate: 0.5 ml/min; UV detection: 208-400 nm.
  • Method 9 MS instrument: Micromass ZQ; HPLC instrument: Waters Alliance 2795; column: Merck Chromolith SpeedROD RP-18e 50 mm ⁇ 4.6 mm; mobile phase A: water+500 ⁇ l of 50% strength formic acid/l, mobile phase B: acetonitrile+500 ⁇ l of 50% strength formic acid/l; gradient: 0.0 min 10% B ⁇ 3.0 min 95% B ⁇ 4.0 min 95% B; oven: 35° C.; flow rate: 0.0 min 1.0 ml/min ⁇ 3.0 min 3.0 ml/min ⁇ 4.0 min 3.0 ml/min; UV detection: 210 nm.
  • Method 10 MS instrument: Micromass ZQ; HPLC instrument: HP 1100 Series; UV DAD; column: Grom-Sil 120 ODS-4 HE 50 mm ⁇ 2 mm, 3.0 ⁇ m; mobile phase A: water+500 ⁇ l of 50% strength formic acid/l, mobile phase B: acetonitrile+500 ⁇ l of 50% strength formic acid/l; gradient: 0.0 min 0% B ⁇ 2.9 min 70% B ⁇ 3.1 min 90% B ⁇ 4.5 min 90% B; oven: 50° C.; flow rate: 0.8 ml/min; WV UV detection: 210 nm.
  • Method 11 (preparative HPLC, separation of enantiomers): column: packing chiral silica gel selector KBD 8361 (250 mm ⁇ 20 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether+5% ethyl acetate; flow rate: 25 ml/min.
  • Method 12 (preparative HPLC, separation of enantiomers): column: packing chiral silica gel selector KBD 5326 (250 mm ⁇ 20 mm) based on the selector poly(N-methacryloyl-L-leucine-dicyclopropylmethylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether+5% ethyl acetate; flow rate: 25 ml/min.
  • Method 13 (preparative HPLC, separation of enantiomers): column: packing chiral silica gel selector KBD 8361 (250 mm ⁇ 20 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether; flow rate: 25 ml/min.
  • Method 14 (preparative HPLC, separation of enantiomers, esters): column: packing chiral silica gel selector KBD 8361 (420 mm ⁇ 100 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: isohexane/ethyl acetate 85/15 v/v; flow rate: 100 ml/min; the compound is dissolved in isohexane/ethyl acetate (85:15).
  • Method 15 (preparative HPLC, separation of enantiomers, esters): column: packing chiral silica gel selector KBD 8361 (420 mm ⁇ 100 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether; flow rate: 100 ml/min; the compound is dissolved in methyl tert-butyl ether.
  • Method 16 instrument: Micromass Platform LCZ with HPLC Agilent Series 1100; column: Grom-SIL120 ODS-4 HE, 50 mm ⁇ 2.0 mm, 3 ⁇ m; mobile phase A: 1 l of water+1 ml of 50% strength formic acid, mobile phase B: 1 l of acetonitrile+1 ml of 50% strength formic acid; gradient: 0.0 min 100% A ⁇ 0.2 min 100% A ⁇ 2.9 min 30% A ⁇ 3.1 min 10% A ⁇ 4.5 min 10% A; oven: 55° C.; flow rate: 0.8 m/min; UV detection: 208-400 nm.
  • Method 17 MS instrument: Micromass ZQ; HPLC instrument: Waters Alliance 2790; column: Grom-Sil 120 ODS-4 HE 50 mm ⁇ 2 mm, 3.0 ⁇ m; mobile phase A: water+500 ⁇ l of 50% strength formic acid/l, mobile phase B: acetonitrile+500 ⁇ l of 50% strength formic acid/l; gradient: 0.0 min 0% B ⁇ 0.2 min 0% B ⁇ 2.9 min 70% B ⁇ 3.1 min 90% B ⁇ 4.5 min 90% B; oven: 45° C.; flow rate: 0.8 ml/min; UV detection: 210 nm.
  • the organic phase is separated off and the aqueous phase is re-extracted with ethyl acetate.
  • the organic phases are combined, washed once with saturated sodium chloride solution and dried over sodium sulphate, and the solvent is concentrated to about half of its original volume.
  • Activated carbon corresponding to 1% of the weight of the nitro compound is then added, and the mixture is heated under reflux for 30 minutes (the colour of the solution changes). The activated carbon is filtered off and the solvent is removed.
  • the residue obtained is an oil which, on drying at RT under high vacuum, forms crystals. Without further purification, the product is directly used for the next step.
  • the reaction flask is thoroughly dried by heating under high vacuum and vented with argon.
  • 1.0 equivalent of the bromoaryl compound and 6.0 equivalents of piperazine in absolute toluene are initially charged in the flask (0.2-0.3M solution of the bromo compound).
  • 0.01 equivalent of tris(dibenzylideneacetone)dipalladium and 0.03 equivalent of BINAP are then added.
  • the reaction mixture is stirred under reflux for 16 h.
  • the mixture is then extracted once with water, the organic phase is extracted twice with 1N hydrochloric acid and the aqueous phase is adjusted to pH 8 using 1N aqueous sodium hydroxide solution and extracted three times with dichloromethane.
  • the combined organic phases are dried over sodium sulphate and filtered, the solvent is removed under reduced pressure and the product is dried under high vacuum overnight.
  • the NMR shows the presence of a varying proportion of non-cyclized reaction product.
  • the mixture of cyclized and non-cyclized product is taken up in dioxane, a spatula tip of silica gel is added and the mixture is stirred under reflux for 30 min to 16 h. The silica gel is filtered off and the solution is used for further reactions.
  • Example 18A 700 mg (1.78 mmol) of methyl (2E)-3- ⁇ 3-fluoro-2-[( ⁇ [2-methoxy-5-(trifluoromethyl)phenyl]-imino ⁇ methylene)amino]phenyl ⁇ -2-propenoate (Example 18A), 352 mg (1.78 mmol) of 1-(3,4-difluorophenyl)piperazine (Example 16A) and a spatula tip of silica gel are stirred in 20 ml of dichloromethane at room temperature for 1 hour and then under reflux for 20 hours. The target compound is then purified by chromatography on silica gel (dichloromethane, dichloromethane/ethyl acetate 10:1).
  • Example 18A 100 mg (0.25 mmol) of methyl (2E)-3- ⁇ 3-fluoro-2-[( ⁇ [2-methoxy-5-(trifluoromethyl)phenyl]-imino ⁇ methylene)amino]phenyl ⁇ -2-propenoate (Example 18A), 45.7 mg (0.25 mmol) of 1-(3-fluorophenyl)piperazine (Example 15A) and a spatula tip of silica gel are stirred in 15 ml of dichloromethane at room temperature for 1 hour and then under reflux for 20 hours. The target compound is obtained after chromatography on silica gel (dichloromethane, dichloromethane/ethyl acetate 10:1).
  • This compound is obtained as enantiomer A by separating the racemate from Example 30A chromatographically according to Method 15 in to into the enantiomers. Starting with 231 g of racemate, 120 g of the target product, which is directly reacted further, are obtained.
  • the compound is obtained as enantiomer A by separating the racemate from Example 31A chromatographically according to Method 15 into the enantiomers. Starting with 231 g of racemate, 111 g (48% of theory) of the target product are obtained.
  • Examples 50A to 112A 111A of Table 1 can be prepared from the corresponding starting materials using the general procedures [A] to [G].
  • the target product is obtained by reacting the enantiomerically pure ester from Example 43A according to the general procedure [H]. Starting with 111 g (0.19 mol) of ester, 69 g (63% of theory) of target product are obtained.
  • the target product is obtained by reacting the enantiomerically pure ester from Example 42A according to the general procedure [11] [H]. Starting with 120 g (0.21 mol) of ester, 96 g (81% of theory) of target product are obtained.
  • Example 34A methyl ⁇ 8-fluoro-2-[4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl ⁇ acetate
  • Example 34A methyl ⁇ 8-fluoro-2-[4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl ⁇ acetate
  • Examples 26 to 34 and 36 to 89 of Table 2 can be prepared from the corresponding starting materials using the general procedures [A] to [H], and Example 35 can be prepared as described below in Table 2.
  • Example 89 80 mg (0.14 mmol) of the methyl ether (Example 89) are dissolved in 2 ml of dichloromethane, and 0.41 mmol of a 1M solution of boron tribromide in dichloromethane is added at 0° C. The mixture is stirred at room temperature for 16 hours, a further 0.82 mmol of the boron tribromide solution is added, followed by a further 1.23 mmol after 24 hours. The reaction mixture is stirred at room temperature for 24 hours and then poured onto ice, and 5 ml of a 1N aqueous hydrochloric acid solution are added. The mixture is extracted with 25 ml of ethyl acetate. The organic phase is washed with a saturated aqueous sodium chloride solution, dried over sodium sulphate, concentrated and purified by preparative HPLC. This gives 50 mg (63% of theory) of product.
  • test compounds are employed as 50 millimolar (mM) solutions in dimethyl sulphoxide (DMSO).
  • DMSO dimethyl sulphoxide
  • Ganciclovir®, Foscarnet® and Cidofovir® are used as reference compounds.
  • 1:2 dilutions are carried out with 50 ⁇ l portions of medium up to row 11 of the 96-well plate.
  • the wells in rows 1 and 12 each contain 50 ⁇ l of medium.
  • the wells are then fixed and stained by adding a mixture of formalin and Giemsa's dye (30 minutes), washed with double-distilled water and dried in a drying oven at 50° C.
  • the plates are then assessed visually using an overhead microscope (Plaque Multiplier from Technomara).
  • EC 50 substance concentration in ⁇ M which inhibits the CPE (cytopathic effect) by 50% compared with the untreated virus control;
  • SI selection index
  • mice 3-4-week old female immunodeficient mice (16-18 g), Fox Chase SCID or Fox Chase SCID-NOD or SCID beige, are purchased from commercial breeders (Taconic M+B, Jackson USA). The animals are housed under sterile conditions (including bedding and feed) in isolators.
  • HCMV Human cytomegalovirus
  • NHDF cells human embryonic prepuce fibroblasts
  • MEM minimal essential medium
  • FCS fetal calf serum
  • DMSO fetal calf serum
  • PBS phosphate-buffered saline
  • the infected sponges are incubated with 25 ⁇ l of PBS/0.1% BSA/1 mM DTT with 5 ng/ ⁇ l basic fibroblast growth factor (bFGF).
  • the immunodeficient mice are anaesthetized with Avertin or a ketamine/xylazine/azepromazine mixture, the fur on the back is removed using a shaver, the epidermis is opened 1-2 cm, unstressed and the moist sponges are transplanted under the dorsal skin. The surgical wound is closed with tissue glue. 6 hours after the transplantation, the mice can be treated for the first time (on the day of the operation, there is one treatment).
  • mice are treated with substance orally three times a day (7.00 h and 14.00 h and 19.00 h), two times a day (8.00 h and 18.00 h) or once a day (14.00 h).
  • the daily dose is, for example 3 or 10 or 30 or 60 or 100 mg/kg of body weight, the volume administered is 10 ml/kg of body weight.
  • the substances are formulated in the form of a 0.5% strength Tylose suspension with 2% DMSO or a 0.5% strength Tylose suspension. 9 days after transplantation and 16 hours after the last administration of substance, the animals are painlessly sacrificed and the sponge is removed.
  • the virus-infected cells are released from the sponge by collagenase digestion (330 U/1.5 ml) and stored in the presence of MEM, 10% fetal calf serum, 10% DMSO at ⁇ 140° C. Evaluation takes place after serial ten-fold dilutions of the virus-infected cells by determining the titer on 24-well plates of confluent NHDF cells after vital staining with Neutral Red. The number of infected cells or infectious virus particles (infectious centre assay) after the substance treatment compared with the placebo-treated control is determined.
  • CYP3A4 To investigate the mechanism-based (irreversible) inhibition of CYP3A4, different concentrations of the test substance are incubated with human liver microsomes (2 mg/ml of microsomal protein) in potassium phosphate buffer pH 7.4 with addition of an NADPH-generating system (NADP+, glucose 6-phosphate, glucose 6-phosphate dehydrogenase) at 37° C. At various points of time, 2 aliquots are taken from the incubation.
  • NADPH-generating system NADP+, glucose 6-phosphate, glucose 6-phosphate dehydrogenase
  • the first aliquot is incubated 1:50 in a new incubation solution (phosphate buffer, NADPH-generating system and 10 ⁇ M of Midazolam) at 37° C. for a further 10 min.
  • the incubation is then stopped using acetonitrile on ice, the protein is pelleted in a centrifuge at 15 000 g and the supernatant is analysed for formation of 1′-hydroxyimidazolam using standard HPLC/MS methods.
  • the second aliquot is stopped using acetonitrile on ice and analysed for remaining test substance using HPLC/UV/MS.
  • the two sets of analytical data are determined for irreversible-inhibition-typical parameters (k inact , K i and partition ratio r), and using these data, the test substance is evaluated (cf. A. Madan, et al., in A. D. Rodrigues (ed.) “Drug-Drug Interaction” in “Drugs and the Pharmaceutical Science”, Vol. 116, ISBN 0-8247-0283.2, Marcel Dekker Inc., New York, 2002.).
  • the compounds of the invention can be converted into pharmaceutical preparations in the following ways:
  • Example 1 100 mg of the compound of Example 1, 50 mg of lactose (monohydrate), 50 mg of corn starch (native), 10 mg of polyvinylpyrrolidone (PVP 25) (from BASF, Ludwigshafen, Germany) and 2 mg of magnesium stearate.
  • lactose monohydrate
  • corn starch 50 mg
  • PVP 25 polyvinylpyrrolidone
  • the mixture of active ingredient, lactose and starch is granulated with a 5% strength solution (m/m) of the PVP in water.
  • the granules are then dried and mixed with the magnesium stearate for 5 min.
  • This mixture is compressed using a conventional tablet press (see above for format of the tablet).
  • a guideline for the compressive force used for the compression is 15 kN.
  • 10 ml of oral suspension are equivalent to a single dose of 100 mg of the compound of the invention.
  • Rhodigel is suspended in ethanol, and the active ingredient is added to the suspension.
  • the water is added while stirring.
  • the mixture is stirred for about 6 h until the swelling of the Rhodigel is complete.
  • Example 1 The compound of Example 1 is dissolved together with polyethylene glycol 400 in the water with stirring.
  • the solution is sterilized by filtration (pore diameter 0.22 ⁇ m) and dispensed under aseptic conditions into heat-sterilized infusion bottles. The latter are closed with infusion stoppers and trimmed caps.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.

Description

More than one reissue application has been filed for the reissue of U.S. Pat. No. 7,196,086. The reissue applications are Application Serial No. (the present application), application Ser. No. 15/955,254 (pending on the filing date of this application and abandoned on Nov. 3, 2020) and application Ser. No. 14/682,512 (now U.S. RE46,791), all of which are reissues of U.S. Pat. No. 7,196,086.
This application is a continuation of Reissue application Ser. No. 15/955,254, which was pending on the filing date of this application. This application is an application for reissue of application Ser. No. 10/832,109, which was filed Apr. 26, 2004 and issued on Mar. 27, 2007 as U.S. Pat. No. 7,196,086. Reissue application Ser. No. 15/955,254 is a continuation of Reissue application Ser. No. 14/682,512 and an application for reissue of application Ser. No. 10/832,109 (U.S. Pat. No. 7,196,086). Reissue application Ser. No. 14/682,512 is an application for reissue of application Ser. No. 10/832,109 (U.S. Pat. No. 7,196,086). Reissue application Ser. No. 14/682,512 matured into Reissue U.S. Pat. No. RE46,791 on Apr. 17, 2018.
The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
The synthesis of dihydroquinazolines is described in Saito T., et al. Tetrahedron Lett., 1996, 37, 209-212 and in Wang F., et al. Tetrahedron Lett., 1997, 38, 8651-8654.
Although agents with antiviral activity and a different structure are available on the market, it is always possible for resistance to develop. Novel agents for an effective therapy are therefore desirable.
One object of the present invention is therefore to provide novel compounds having the same or improved antiviral effect for the treatment of viral infective diseases in humans and animals.
It has been found, surprisingly, that the substituted dihydroquinazolines described in the present invention have antiviral effect.
The present invention provides compounds of the formula
Figure USRE049698-20231017-C00001

in which
  • Ar represents aryl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl, amino, alkylamino, aminocarbonyl and nitro,
    • where alkyl may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of halogen, amino, alkylamino, hydroxyl and aryl,
    • or two of the substituents on the aryl radical together with the carbon atoms to which they are attached form a 1,3-dioxolane, a cyclopentane ring or a cyclohexane ring, and any third substituent present is selected independently from the group mentioned,
  • R1 represents hydrogen, amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro or trifluoromethyl,
  • R2 represents hydrogen, alkyl, alkoxy, alkylthio, cyano, halogen, nitro or trifluoromethyl,
  • R3 represents amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro, trifluoromethyl, alkylsulphonyl or alkylaminosulphonyl
    or
    one of the radicals R1, R2 and R3 represents hydrogen, alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl and the other two together with the carbon atoms to which they are attached form a 1,3-dioxolane, a cyclopentane ring or a cyclohexane ring,
  • R4 represents hydrogen or alkyl,
  • R5 represents hydrogen or alkyl
    or
    the radicals R4 and R5 are attached to carbon atoms directly opposing each other in the piperazine ring and form a methylene bridge which is optionally substituted by 1 or 2 methyl groups,
  • R6 represents alkyl, alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,
  • R7 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro
    and
  • R8 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro, and their salts, their solvates and the solvates of their salts.
Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts, compounds mentioned below as embodiment(s) and their salts, solvates and solvates of the salts, unless the compounds below, embraced by formula (I), are already salts, solvates and solvates of the salts.
The compounds according to the invention may, depending on their structure, exist in stereoisomeric forms (enantiomers, diastereomers). The invention therefore relates to the enantiomers or diastereomers and respective mixtures thereof. The stereoisomerically pure constituents can be isolated in a known manner from such mixtures of enantiomers and/or diastereomers.
If the compounds according to the invention may exist in tautomeric forms, the present invention embraces all such tautomeric forms.
Salts which are preferred for the purposes of the present invention are physiologically acceptable salts of the compounds according to the invention. However, the invention also embraces salts which are per se not suitable for pharmaceutical applications but can be used, for example, for isolating or purifying the compounds according to the invention.
Physiologically acceptable salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulphonic acids, for example salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and preferably, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, such as, by way of example and preferably, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine.
Solvates refer for the purposes of the invention to those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates in which the coordination takes place with water.
For the purposes of the present invention, unless specified otherwise, the substituents have the following meanings:
Alkyl per se and “alk” and “alkyl” in alkoxy, alkylamino, alkylcarbonyl, alkylsulphonyl, alkylaminosulphonyl and alkoxycarbonyl are a straight-chain or branched alkyl radical having generally 1 to 6, preferably 1 to 4, particularly preferably 1 to 3, carbon atoms, by way of example and preferably methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.
Alkoxy is, by way of example and preferably, methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
Alkylamino is an alkylamino radical having one or two alkyl substituents (chosen independently of one another), by way of example and preferably methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n-hexylamino, N,N-dimethylamino, N,N-diethylamino, N-ethyl-N-methylamino, N-methyl-N-n-propylamino, N-isopropyl-N-n-propyl-amino, N-tert-butyl-N-methylamino, N-ethyl-N-n-pentylamino and N-n-hexyl-N-methylamino. C1—C3-alkylamino is, for example, a monoalkylamino radical having 1 to 3 carbon atoms or a dialkylamino radical having in each case 1 to 3 carbon atoms per alkyl substituent.
Alkylsulphonyl is, by way of example and preferably, methylsulphonyl, ethylsulphonyl, n-propyl-sulphonyl, iso-propylsulphonyl, tert-butylsulphonyl, n-pentylsulphonyl and n-hexylsulphonyl.
Alkylaminosulphonyl is an alkylaminosulphonyl radical having one or two alkyl substituents (chosen independently of one another), by way of example and preferably methylaminosulphonyl, ethylaminosulphonyl, n-propylaminosulphonyl, isopropylaminosulphonyl, tert-butylaminosulphonyl, n-pentylaminosulphonyl, n-hexyl-aminosulphonyl, N-N-dimethylaminosulphonyl, N-N-diethyl-aminosulphonyl, N-ethyl-N-methylaminosulphonyl, N-methyl-N-n-propylamiinosulphonyl N-methyl-N-n-propylaminosulphonyl, N-isopropyl-N-n-propyl-aminosulphonyl, N-tert-butyl-N-methylaminosulphonyl, N-ethyl-N-n-pentyl-aminosulphonyl and N-n-hexyl-N-methylaminosulphonyl. C1—C3-alkylaminosulphonyl is, for example, a monoalkylaminosulphonyl radical having 1 to 3 carbon atoms or a dialkylaminosulphonyl radical having in each case 1 to 3 carbon atoms per alkyl substituent.
Alkylcarbonyl is, by way of example and preferably, acetyl and propanoyl.
Alkoxycarbonyl is, by way of example and preferably, methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, iso-propoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxy-carbonyl.
Aryl is a mono- to tricyclic aromatic carbocyclic radical having generally 6 to 14 carbon atoms; by way of example and preferably phenyl, naphthyl and phenanthrenyl.
Halogen is fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine.
A symbol * on a carbon atoms means that the compound, with respect to the configuration at this carbon atom, is present in enantiomerically pure form which, for the purposes of the present invention, is to be understood as meaning an enantiomeric excess of more than 90% (>90% ee).
Preference is given to those compounds of the formula (I) in which
  • Ar represents phenyl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of C1—C6-alkyl, C1—C6-alkoxy, carboxyl, C1—C6-alkylcarbonyl, C1—C6-alkoxycarbonyl, trifluoromethyl, fluorine, chlorine, bromine, cyano, hydroxyl, amino, C1—C6-alkylamino and nitro,
    • or two of the substituents on the phenyl radical together with the carbon atoms to which they are attached form a 1,3-dioxolane and any third substituent present is selected independently from the group mentioned,
  • R1 represents hydrogen, C1—C3-alkyl, C1—C3-alkoxy, C1—C3-alkylthio, fluorine or chlorine,
  • R2 represents hydrogen, C1—C3-alkyl, C1—C3-alkoxy, C1—C3-alkylthio, fluorine or chlorine,
  • R3 represents C1—C4-alkyl, cyano, fluorine, chlorine, nitro, trifluoromethyl or C1—C3-alkylsulphonyl,
    or
    one of the radicals R1, R2 and R3 represents hydrogen, C1—C3-alkyl, C1—C3-alkoxy, cyano, halogen, nitro or trifluoromethyl and the other two together with the carbon atoms to which they are attached form a cyclopentane ring or a cyclohexane ring,
  • R4 represents hydrogen or methyl,
  • R5 represents hydrogen,
  • R6 represents C1—C3-alkyl, C1—C3-alkoxy, carboxyl, aminocarbonyl, trifluoromethyl, fluorine, chlorine, cyano, hydroxyl or nitro,
  • R7 represents hydrogen, C1—C3-alkyl, C1—C3-alkoxy, fluorine, chlorine, cyano or hydroxyl
    and
  • R8 represents hydrogen, C1—C3-alkyl, C1—C3-alkoxy, fluorine, chlorine, cyano or hydroxyl.
Among these, particular preference is given to those compounds of the formula (I), in which
  • Ar represents phenyl which may be substituted by 1 or 2 substituents, where the substituents are selected independently of one another from the group consisting of methyl, methoxy, fluorine and chlorine,
  • R1 represents hydrogen, methyl, methoxy, methylthio, fluorine or chlorine,
  • R2 represents hydrogen,
  • R3 represents methyl, isopropyl, tert-butyl, cyano, fluorine, chlorine, nitro or trifluoromethyl,
  • R4 represents hydrogen,
  • R5 represents hydrogen,
  • R6 represents aminocarbonyl, fluorine, chlorine, cyano or hydroxyl,
  • R7 represents hydrogen
    and
  • R8 represents hydrogen, fluorine or chlorine.
Among these, particular preference is also given to those compounds of the formula (I), in which
  • Ar represents phenyl which may be substituted by 1 or 2 substituents, where the substituents are selected independently of one another from the group consisting of methyl, methoxy, fluorine and chlorine,-
  • R1 represents hydrogen, methyl, methoxy, methylthio, fluorine or chlorine,
  • R2 represents hydrogen,
  • R3 represents methyl, tert-butyl, cyano, fluorine, chlorine, nitro or trifluoromethyl,
  • R4 represents hydrogen,
  • R5 represents hydrogen,
  • R6 represents aminocarbonyl, fluorine, chlorine, cyano or hydroxyl,
  • R7 represents hydrogen
    and
  • R8 represents hydrogen, fluorine or chlorine.
Among these, very particular preference is given to those compounds of the formula (I), in which
  • Ar represents phenyl which may be substituted by 1 or 2 substituents, where the substituents are selected independently of one another from the group consisting of methyl, methoxy, fluorine and chlorine,
  • R1 represents hydrogen or methoxy,
  • R2 represents hydrogen,
  • R3 represents methyl, tert-butyl, chlorine or trifluoromethyl,
  • R4 represents hydrogen,
  • R5 represents hydrogen,
  • R6 represents aminocarbonyl or fluorine,
  • R7 represents hydrogen
    and
  • R8 represents hydrogen or fluorine.
Preference is also given to those compounds of the formula (I), in which R1 represents hydrogen, methyl, methoxy or fluorine.
Among these, particular preference is given to those compounds of the formula (I), in which R1 represents methoxy.
Preference is also given to those compounds of the formula (I) in which R1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring. For the purposes of the present invention, the point of attachment of the phenyl ring substituted by radicals R1, R2 and R3 is to be understood as meaning the carbon atom of the phenyl ring which, according to formula (I), is attached to one of the two nitrogen atoms of the dihydroquinazoline.
Particular preference is given to those compounds of the formula (I), in which R1 represents methoxy and R1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring.
Preference is also given to those compounds of the formula (I) in which R2 represents hydrogen.
Preference is also given to those compounds of the formula (I) in which R3 represents trifluoromethyl, chlorine, methyl, isopropyl or tert-butyl.
Among these, particular preference is given to those compounds of the formula (D) (I) in which R3 represents trifluoromethyl, chlorine or methyl.
Among these, very particular preference is given to those compounds of the formula (I) in which R3 represents trifluoromethyl.
Preference is also given to those compounds of the formula (I) in which R1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring and R3 is attached to the phenyl ring via the position meta to the point of attachment of the phenyl ring, which position is opposite to that of R1.
Particular preference is given to those compounds of the formula (I) in which R1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring, R3 represents trifluoromethyl, chlorine or methyl and R3 is attached to the phenyl ring via the position meta to the point of attachment of the phenyl ring, which position is opposite to that of R1.
Among these, particular preference is given to those compounds of the formula (I) in which R1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring, R3 represents trifluoromethyl and R3 is attached to the phenyl ring via the position meta to the point of attachment of the phenyl ring, which position is opposite to that of R1.
Preference is also given to those compounds of the formula (I) in which R4 and R5 represent hydrogen.
Preference is also given to those compounds of the formula (I) in which R6 represents fluorine.
Particular preference is given to those compounds of the formula (I) in which R6 represents fluorine and R6 is, as described in formula
Figure USRE049698-20231017-C00002

attached to the aromatic radical of the dihydroquinazoline.
Preference is also given to those compounds of the formula (I) in which R7 represents hydrogen.
Among these, particular preference is given to those compounds of the formula (I) in which R8 represents hydrogen, methyl or fluorine.
Among these, very particular preference is given to those compounds of the formula (I) in which R8 represents hydrogen.
Preference is also given to those compounds of the formula (I) in which Ar represents phenyl which may be substituted by 1 or 2 substituents, where the substituents are selected independently of one another from the group consisting of methyl, methoxy, fluorine and chlorine.
The particular radical definitions given in the respective combinations or preferred combinations of radicals are, independently of the combinations of radicals given in each case, also replaced by radical definitions of other combinations.
Very particular preference is given to combinations of two or more of the preferred ranges mentioned above.
The invention furthermore provides a process for preparing the compounds of the formula (I), which comprises reacting compounds of the formula
Figure USRE049698-20231017-C00003

in which
  • Ar, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined above and
  • R9 represents alkyl, preferably methyl or ethyl or tert-butyl, with bases or acids.
In the case of methyl and ethyl, the reaction is generally carried out using bases in inert solvents, preferably in a temperature range of from room temperature to the reflux temperature of the solvent, at atmospheric pressure.
Suitable bases are, for example, alkali metal hydroxides, such as sodium hydroxide, lithium hydroxide or potassium hydroxide, or alkali metal carbonates, such as caesium carbonate, sodium carbonate or potassium carbonate, if appropriate in aqueous solution; preference is given to sodium hydroxide in water.
Inert solvents are, for example, ethers, such as 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, alcohols, such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, or mixtures of solvents; preference is given to dioxane or tetrahydrofuran.
In the case of tert-butyl, the reaction is generally carried out using acids in inert solvents, preferably in a temperature range of from 0° C. to 40° C., at atmospheric pressure.
Here, suitable acids are hydrogen chloride in dioxane, hydrogen bromide in acetic acid or trifluoroacetic acid in methylene chloride.
The compounds of the formula (II) are known or can be prepared by reacting compounds of the formula
Figure USRE049698-20231017-C00004

in which
R6, R7, R8 and R9 are as defined above
in a two-step reaction initially with compounds of the formula
Figure USRE049698-20231017-C00005

in which
  • R1, R2 and R3 are as defined above
    and then with compounds of the formula
Figure USRE049698-20231017-C00006

in which
  • Ar, R4 and R5 are as defined above.
Both steps of the reaction are generally carried out in inert solvents, preferably in a temperature range of from room temperature to 100° C., at atmospheric pressure. In the second step, if appropriate, silica gel is added to the reaction mixture. The reaction is preferably carried out with work-up between the first and the second step.
Suitable inert solvents are, for example, halogenated hydrocarbons, such as methylene chloride, trichloromethane, carbon tetrachloride, trichloroethane, tetrachloroethane, 1,2-dichloroethane or trichloroethylene, ethers, such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents, such as dimethylformamide, dimethylacetamide, acetonitrile or ethyl acetate, or mixtures of solvents; preference is given to methylene chloride.
The compounds of the formula (IV) are known or can be synthesized by known processes from the corresponding starting materials.
The compounds of the formula (V) are known or can be synthesized by known processes from the corresponding starting materials, for example by a Buchwald-Hartwig reaction according to the synthesis scheme below (review in: C. G. Frost, P. Mendonca, J. Chem. Soc., Perkin Trans I, 1998, 2615-2623):
Figure USRE049698-20231017-C00007
The starting materials required for this purpose are known or can be synthesized by known processes from the corresponding starting materials.
The compounds of the formula (M) (III) are known or can be prepared by reacting compounds of the formula
Figure USRE049698-20231017-C00008

in which
  • R6, R7, R8 and R9 are as defined above
    with triphenylphosphine and carbon tetrachloride.
The reaction is generally carried out in inert solvents, in the presence of a base, preferably in a temperature range of from room temperature to 50° C., at atmospheric pressure.
Suitable inert solvents are, for example, ethers, such as diethyl ether, methyl tert-butyl ether, 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents, such as dimethylformamide, dimethylacetamide, acetonitrile or pyridine; preference is given to acetonitrile.
Suitable bases are, for example, alkali metal and alkaline earth metal carbonates, such as caesium carbonate, sodium carbonate or potassium carbonate, or amines, such as triethylamine, diisopropylethylamine, N-methylmorpholine or pyridine; preference is given to triethylamine.
The compounds of the formula (VI) are known or can be synthesized by known processes from the corresponding starting materials, for example by a Heck reaction or a Wittig-Homer Wittig-Horner reaction, according to the synthesis schemes below:
Figure USRE049698-20231017-C00009
The starting materials required for this purpose are known or can be synthesized by known processes from the corresponding starting materials.
The preparation of the compounds according to the invention can be illustrated by the synthesis scheme below.
Figure USRE049698-20231017-C00010
The compounds of the general formula (I) according to the invention show a surprising range of effects which could not have been predicted. They show an antiviral effect on representatives of the group of the Herpes viridae (Herpes viruses), especially on cytomegalo viruses (CMV), in particular, on human cytomegalovirus (HCMV).
Areas of indication which may be mentioned by way of example are:
  • 1) Treatment and prophylaxis of HCMV infections in AIDS patients (retinitis, pneumonitis, gastrointestinal infections).
  • 2) Treatment and prophylaxis of cytomegalovirus infections in bone-marrow and organ transplantations which develop often life-threatening HCMV pneumonitis or encephalitis, and gastrointestinal and systemic HCMV infections.
  • 3) Treatment and prophylaxis of HCMV infections in neonates and infants.
  • 4) Treatment of an acute HCMV infection in pregnant women.
  • 5) Treatment of HCMV infection in immunosuppressed patients associated with cancer and cancer therapy.
  • 6) Treatment of HCMV-positive cancer patients with the aim to reduce HCMV-mediated tumour progression (cf. J. Cinatl, et al., FEMS Microbiology Reviews 2004, 28, 59-77).
The present invention further provides the use of the compounds according to the invention for the treatment and/or prophylaxis of diseases, especially of infections with viruses, in particular the viruses mentioned above, and the infective diseases caused by these infections. Hereinbelow, a viral infection is to be understood as including both an infection with a virus and a disease caused by an infection with a virus.
The present invention also provides the use of the compounds according to the invention for the treatment and/or prophylaxis of disorders, in particular the disorders mentioned above.
The present invention also provides the use of the compounds according to the invention for preparing a medicament for the treatment and/or prophylaxis of disorders, in particular the disorders mentioned above.
The compounds according to the invention are preferably used for preparing medicaments suitable for the prophylaxis and/or treatment of infections with a representative of the group of the Herpes viridae, in particular a cytomegalovirus, in particular the human cytomegalovirus.
The present invention also provides a method for the treatment and/or prophylaxis of disorders, in particular the disorders mentioned above, using an antivirally effective amount of the compounds according to the invention.
The present invention also provides medicaments comprising at least one compound according to the invention and at least one or more further active compounds, in particular for the treatment and/or prophylaxis of the disorders mentioned above. Active compounds suitable for combinations are, by way of example and preferably: antiviral active compounds, such as gancyclovir or acyclovir.
The compounds according to the invention can act systemically and/or locally. For this purpose, they can be administered in a suitable way, such as, for example, by the oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival or otic route, or as implant or stent.
For these administration routes, it is possible to administer the compounds according to the invention in suitable administration forms.
Suitable for oral administration are known administration forms which deliver the compounds according to the invention rapidly and/or in modified form and which comprise the compounds according to the invention in crystalline and/or amorphous and/or dissolved form, such as, for example, tablets (uncoated or coated tablets, for example tablets provided with enteric coatings or coatings which dissolve slowly or are insoluble and which control the release of the compound according to the invention), tablets which disintegrate rapidly in the oral cavity and/or films/wafers, films/lyophylisates, capsules (for example Hart or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
Parenteral administration can take place with avoidance of an adsorption step (for example intravenously, intraarterially, intracardially, intraspinally or intralumbally) or with inclusion of absorption (for example intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally). Administration forms suitable for parenteral administration are, inter alia, preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
Examples suitable for other administration routes are, for example, pharmaceutical forms for inhalation (inter alia powder inhalers, nebulizers), nasal drops/solutions/sprays; tablets to be administered lingually, sublingually or buccally, films/wafers or capsules, suppositories, preparations for the eyes or ears, vaginal capsules, aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems, milk, pastes, foams, dusting powders, implants or stents.
The compounds according to the invention can be converted into the stated administration forms.
This can take place in a known manner with the mixing of inert, non-toxic, pharmaceutically acceptable auxiliaries. These auxiliaries include, inter alia, carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecyl sulphate, polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (for example antioxidants such as ascorbic acid), colorants (for example inorganic pigments such as iron oxides) and flavour- and/or odour-masking agents.
The present invention furthermore provides medicaments comprising at least one compound according to the invention, usually together with one or more inert, non-toxic, pharmaceutically acceptable auxiliaries, and their use for the purposes mentioned above.
In general, it has proved advantageous to administer on intravenous administration amounts of about 0.001 to 10 mg/kg, preferably about 0.01 to 5 mg/kg, of body weight to achieve effective results, and the dosage on oral administration is about 0.01 to 25 mg/kg, preferably 0.1 to 10 mg/kg, of body weight.
It may nevertheless be necessary where appropriate to deviate from the amounts mentioned, specifically as a function of the body weight, administration route, individual response to the active compound, mode of preparation and time or interval over which administration takes place. Thus, it may be sufficient in some cases to make do with less than the aforementioned minimal amount, whereas in other cases the upper limit mentioned must be exceeded. It may in the event of administration of larger amounts be advisable to divide these into a plurality of individual doses over the day.
The percentage data in the following tests and examples are percentages by weight unless otherwise indicated; parts or parts by weight. Solvent ratios, dilution ratios and concentration data of liquid/liquid solutions are in each case based on volume.
A. EXAMPLES
Abbreviations:
  • BINAP 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl
  • CDCl3 deuterated chloroform
  • DCI direct chemical ionization (in MS)
  • DCM dichloromethane
  • DIEA N,N-diisopropylethylamine
  • DMSO dimethyl sulphoxide
  • DMF N,N-dimethylformamide
  • EA ethyl acetate
  • EI electron impact ionization (in MS)
  • ESI electrospray ionization (in MS)
  • h hour
  • HPLC high-pressure, high-performance liquid chromatography
  • LC-MS liquid-chromatography-coupled mass spectroscopy
  • LDA lithium diisopropylamide
  • min minutes
  • m.p. melting point
  • MS mass spectroscopy
  • MTBE methyl tert-butyl ether
  • NMR nuclear magnetic resonance spectroscopy
  • Pd-C palladium-on-carbon
  • RP-HPLC reverse phase HPLC
  • RT room temperature
  • Rt retention time (in HPLC)
  • THF tetrahydrofuran
  • TLC Thin-layer chromatography.
    General LC-MS and HPLC methods:
Method 1 (analytical HPLC): column: Kromasil C18 60 mm×2 mm; temperature: 30° C.; flow rate: 0.75 ml/min; mobile phase A: 0.005 M HClO4, mobile phase B: acetonitrile; gradient: →0.5 min 98% A, →4.5 min 10% A, →6.5 min 10% A.
Method 2 (preparative HPLC): column: GromSil C18, 250 mm×30 mm; flow rate: 50 ml/min; time per run: 38 min; detection: 210 nm; mobile phase A: water, mobile phase B: acetonitrile; gradient: 10% B (3 min)->90% B (31 min)->90% B (34 min)->10% B (34.01 min).
Method 3 (LC-MS): column: GromSil 120 ODS-4 HE, 50 mm×2.0 mm, 3 μm; mobile phase A: 1 l of water+1 ml of 50% strength formic acid, mobile phase B: 1 l of acetonitrile+1 ml of 50% strength formic acid; gradient: 0.0 min 100% A→0.2 min 100% A→2.9 min 30% A→3.1 min 10% A→4.5 min 10% A; oven: 55° C.; flow rate: 0.8 ml/min; UV detection: 208-400 nm.
Method 4 (preparative HPLC, separation of enantiomers, carboxylic acids): column: packing chiral silica gel selector KBD 8361 (420 mm×100 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide) poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether; flow rate: 100 ml/min; the compound is dissolved in methyl tert-butyl ether/ethyl acetate (9:1).
Method 5 (preparative HPLC): column: GromSil C18, 250 mm×30 mm; flow rate: 50 ml/min; time per run: 38 min; detection: 210 nm; mobile phase A: water with 0.1% formic acid, mobile phase B: acetonitrile; gradient: 10% B (3 min)->90% B (31 min)->90% B (34 min)->10% B (34.01 min).
Method 6 (analytical HPLC): instrument: HP 1100 with DAD detection; column: Kromasil RP-18, 60 mm×2 mm, 3.5 μm; mobile phase A: 5 ml of HClO4/l of water, mobile phase B: acetonitrile; gradient: 0 min 2% B, 0.5 min 2% B, 4.5 min 90% B, 9 min 90% B; flow rate: 0.75 ml/min; temp.: 30° C.; detection: UV 210 nm.
Method 7 (LC-MC): instrument: Micromass Platform LCZ with HPLC Agilent series 1100; column: GromSIL120 ODS-4 HE, 50 mm×2.0 mm, 3 μm; mobile phase A: 1 l of water+1 ml of 50% strength formic acid, mobile phase B: 1 l of acetonitrile+1 ml of 50% strength formic acid; gradient: 0.0 min 100% A→0.2 min 100% A→2.9 min 30% A→3.1 min 10% A→4.5 min 10% A; oven: 55° C.; flow rate: 0.8 ml/min; UV detection: 210 nm.
Method 8 (LC-MC): instrument: Micromass Platform LCZ, HP 1100; column: Symmetry C18, 50 mm×2.1 mm, 3.5 μm; mobile phase A: acetonitrile+0.1% formic acid, mobile phase B: water+0.1% formic acid; gradient: 0.0 min 10% A→4.0 min 90% A→6.0 min 90% A; oven: 40° C.; flow rate: 0.5 ml/min; UV detection: 208-400 nm.
Method 9 (LC-MC): MS instrument: Micromass ZQ; HPLC instrument: Waters Alliance 2795; column: Merck Chromolith SpeedROD RP-18e 50 mm×4.6 mm; mobile phase A: water+500 μl of 50% strength formic acid/l, mobile phase B: acetonitrile+500 μl of 50% strength formic acid/l; gradient: 0.0 min 10% B→3.0 min 95% B→4.0 min 95% B; oven: 35° C.; flow rate: 0.0 min 1.0 ml/min→3.0 min 3.0 ml/min→4.0 min 3.0 ml/min; UV detection: 210 nm.
Method 10 (LC-MC): MS instrument: Micromass ZQ; HPLC instrument: HP 1100 Series; UV DAD; column: Grom-Sil 120 ODS-4 HE 50 mm×2 mm, 3.0 μm; mobile phase A: water+500 μl of 50% strength formic acid/l, mobile phase B: acetonitrile+500 μl of 50% strength formic acid/l; gradient: 0.0 min 0% B→2.9 min 70% B→3.1 min 90% B→4.5 min 90% B; oven: 50° C.; flow rate: 0.8 ml/min; WV UV detection: 210 nm.
Method 11 (preparative HPLC, separation of enantiomers): column: packing chiral silica gel selector KBD 8361 (250 mm×20 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether+5% ethyl acetate; flow rate: 25 ml/min.
Method 12 (preparative HPLC, separation of enantiomers): column: packing chiral silica gel selector KBD 5326 (250 mm×20 mm) based on the selector poly(N-methacryloyl-L-leucine-dicyclopropylmethylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether+5% ethyl acetate; flow rate: 25 ml/min.
Method 13 (preparative HPLC, separation of enantiomers): column: packing chiral silica gel selector KBD 8361 (250 mm×20 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether; flow rate: 25 ml/min.
Method 14 (preparative HPLC, separation of enantiomers, esters): column: packing chiral silica gel selector KBD 8361 (420 mm×100 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: isohexane/ethyl acetate 85/15 v/v; flow rate: 100 ml/min; the compound is dissolved in isohexane/ethyl acetate (85:15).
Method 15 (preparative HPLC, separation of enantiomers, esters): column: packing chiral silica gel selector KBD 8361 (420 mm×100 mm) based on the selector poly(N-methacryloyl-L-leucine-1-menthylamide poly(N-methacryloyl-L-leucine-1-methylamide); temperature: 23° C.; mobile phase: methyl tert-butyl ether; flow rate: 100 ml/min; the compound is dissolved in methyl tert-butyl ether.
Method 16 (LC-MS): instrument: Micromass Platform LCZ with HPLC Agilent Series 1100; column: Grom-SIL120 ODS-4 HE, 50 mm×2.0 mm, 3 μm; mobile phase A: 1 l of water+1 ml of 50% strength formic acid, mobile phase B: 1 l of acetonitrile+1 ml of 50% strength formic acid; gradient: 0.0 min 100% A→0.2 min 100% A→2.9 min 30% A→3.1 min 10% A→4.5 min 10% A; oven: 55° C.; flow rate: 0.8 m/min; UV detection: 208-400 nm.
Method 17 (LC-MS): MS instrument: Micromass ZQ; HPLC instrument: Waters Alliance 2790; column: Grom-Sil 120 ODS-4 HE 50 mm×2 mm, 3.0 μm; mobile phase A: water+500 μl of 50% strength formic acid/l, mobile phase B: acetonitrile+500 μl of 50% strength formic acid/l; gradient: 0.0 min 0% B→0.2 min 0% B→2.9 min 70% B→3.1 min 90% B→4.5 min 90% B; oven: 45° C.; flow rate: 0.8 ml/min; UV detection: 210 nm.
Starting Materials
General Procedure [A]: Synthesis of Substituted 2-aminocinnamic Acid Derivatives by Heck Coupling from 2-halo-substituted Anilines
In a one-necked flask, 1.0 equivalent of an aryl halide is initially charged with 1.6 equivalents of methyl acrylate or tert-butyl acrylate, 2.0 equivalents of triethylamine, 0.03 equivalents of palladium(II) acetate and 0.03 equivalents of trio-tolylphosphine tri-o-tolylphosphine in acetonitrile (solution about 1M). The mixture is stirred under reflux for 48 hours. After the reaction has ended (the reaction is monitored by TLC), the solvent is removed. The residue is purified chromatographically on silica gel using cyclohexane/ethyl acetate=8:2 v/v.
Example 1A
Methyl (2E)-3-[2-amino-3-fluorophenyl]propenoate
Figure USRE049698-20231017-C00011
Starting with 42.00 g (221.04 mmol) of 2-bromo-6-fluoroaniline, the general procedure [A] gives 29.66 g (68% of theory) of product.
HPLC (Method 1): Rt=4.14 min
MS (ESI-pos): m/z=196 (M+H)+
Example 2A
Methyl 2-amino-3-[(1E)-3-methoxy-3-oxo-1-propenyl]benzoate
Figure USRE049698-20231017-C00012
Starting with 2.00 g (8.69 mmol) of methyl 2-amino-3-bromobenzoate, the general procedure [A] gives 1.29 g (60% of theory) of product.
HPLC (Method 1): Rt=4.42 min
MS (ESI-pos): m/z=236 (M+H)+
Example 3A
Methyl (2E)-3-(2-amino-3,5-difluorophenyl)-2-propenoate
Figure USRE049698-20231017-C00013
Starting with 3.00 g (14.42 mmol) of 2-bromo-4,6-difluoroaniline, the general procedure [A] gives 1.41 g (45% of theory) of product.
HPLC (Method 1): Rt=4.23 min
MS (ESI-pos): m/z=214 (M+H)+
Example 4A
Methyl 4-amino-3-[(1E)-3-methoxy-3-oxo-1-propenyl]benzoate
Figure USRE049698-20231017-C00014
Starting with 25.00 g (90.23 mmol) of methyl 4-amino-3-iodobenzoate, the general procedure [A] gives 24.31 g (92% of theory) of product.
HPLC (Method 1): Rt=4.71 min
MS (ESI-pos): m/z=278 (M+H)+
Example 5A
Methyl (2E)-3-[2-amino-5-cyanophenyl]-2-propenoate
Figure USRE049698-20231017-C00015
Starting with 1.90 g (9.64 mmol) of 3-bromo-4-aminobenzonitrile, the general procedure [A] gives 1.28 g (50% of theory) of product.
HPLC (Method 1): Rt=2.85 min
MS (DCI-pos): m/z=220 (M+NH4)+
General Procedure [B]: Synthesis of substituted 2-nitrocinnamic acid derivatives by Wittig-Horner reaction from 2-halo-substituted benzaldehydes
In a 100 ml one-necked flask, 27.5 mmol of methyl diethyl phosphonoacetate, 25.0 mmol of the benzaldehyde and 27.5 mmol of lithium hydroxide are suspended in tetrahydrofuran. After the reaction has ended (the reaction is monitored by TLC), the reaction mixture is mixed with the same volume of water. The aqueous phase is extracted three times with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution and dried over sodium sulphate, and the solvent is removed. The product is dried under high vacuum at RT, without further purification. If the product is very impure, it is, if appropriate, purified by column chromatography on silica gel using cyclohexane/ethyl acetate.
Example 6A
Methyl (2E)-3-(3-methoxy-2-nitrophenyl)-2-propenoate
Figure USRE049698-20231017-C00016
Starting with 2.00 g (11.04 mmol) of 3-methoxy-2-nitrobenzaldehyde, the general procedure [B] gives 2.46 g (92% of theory) of product.
HPLC (Method 1): Rt=4.37 min
MS (ESI-pos): m/z=238 (M+H)+
Example 7A
Methyl (2E)-3-(5-fluoro-2-nitrophenyl)-2-propenoate
Figure USRE049698-20231017-C00017
Starting with 20.0 g (118.3 mmol) of 5-fluoro-2-nitrobenzaldehyde, the general procedure [B] gives 7.25 g (27% of theory) of product.
MS (DCI): m/z=243 (M+NH4)+
General Procedure [C]: Preparation of a 2-nitrobenzaldehyde from a Benzyl Halide
10.0 mmol of the benzyl halide, 4.1 g of molecular sieve 4 Å and 20.0 mmol of N-methylmorpholine N-oxide are suspended in 45 ml of acetonitrile. The mixture is stirred at RT until the reaction has gone to completion (the reaction is monitored by TLC). After the reaction has ended, the molecular sieve is filtered off, the solvent is removed and the residue is taken up again in ethyl acetate. This solution is initially washed with 1N hydrochloric acid and then with saturated sodium chloride solution. The organic phase is separated off and then dried over sodium sulphate, and the solvent is again removed. Analysis shows that the crude product is sufficiently pure and can directly be reacted further.
Example 8A
2-Fluoro-6-nitrobenzaldehyde
Figure USRE049698-20231017-C00018
Starting with 2.00 g (8.55 mmol) of 3-fluoro-6-nitrobenzyl bromide, the general procedure [C] gives 1.09 g (75% of theory) of product.
HPLC (Method 1): Rt=3.58 min
General Procedure [D]: Reduction of the Nitro Group of the 2-nitrocinnamic Acid Derivatives
Under argon, 25 mmol of the nitro compound and 125 mmol of tin(II) chloride dihydrate are initially charged in 60 ml of absolute ethanol in a 250 ml two-necked flask. This suspension is stirred under reflux for 30 minutes, and a clear solution is formed. The solution is then cooled to room temperature and subsequently poured onto ice-water. Using either solid sodium bicarbonate or a saturated sodium carbonate solution, the pH is adjusted to pH=7-8. 60 ml of ethyl acetate are then added, and the precipitated tin salts are filtered off through kieselguhr (a layer of a thickness of about 1 cm). The organic phase is separated off and the aqueous phase is re-extracted with ethyl acetate. The organic phases are combined, washed once with saturated sodium chloride solution and dried over sodium sulphate, and the solvent is concentrated to about half of its original volume. Activated carbon corresponding to 1% of the weight of the nitro compound is then added, and the mixture is heated under reflux for 30 minutes (the colour of the solution changes). The activated carbon is filtered off and the solvent is removed.
The residue obtained is an oil which, on drying at RT under high vacuum, forms crystals. Without further purification, the product is directly used for the next step.
Example 9A
Methyl 3-[2-amino-6-fluorophenyl]propenoate
Figure USRE049698-20231017-C00019
Starting with 7.25 g (32.2 mmol) of the nitro compound from Example 7A, the general procedure [D] gives 5.0 g (58% of theory) of product.
HPLC (Method 1): Rt=3.33 min
General Procedure [E]: Synthesis of the Iminophosphoranes by Appel Reaction of the Substituted Anilines
In a 50 ml one-necked flask, 10.0 mmol of the amine of the 2-aminocinnamic ester, 20.0 mmol of triphenylphosphine, 100.0 mmol of carbon tetrachloride and 100.0 mmol of triethylamine are dissolved in 20 ml of acetonitrile. The mixture is stirred at room temperature for 2 hours. After the reaction has ended (the reaction is monitored by TLC or analytic HPLC), the solvent is removed under reduced pressure and the residue is purified by column chromatography on silica gel using cyclohexane/ethyl acetate=7:3.
Example 10A
Methyl (2E)-3-{3-fluoro-2-[(triphenylphosphoranylidene)amino]phenyl}propenoate
Figure USRE049698-20231017-C00020
Starting with 29.3 g (150.1 mmol) of the amine compound from Example 1A, the general procedure [E] gives 55.0 g (80% of theory) of product.
HPLC (Method 1): Rt=4.46 min
MS (ESI-pos): m/z=456 (M+H)+
Example 11A
Methyl (2E)-3-{5-fluoro-2-[(triphenylphosphoranylidene)amino]phenyl}propenoate
Figure USRE049698-20231017-C00021
Starting with 50.0 g (256.2 mmol) of the amine compound from Example 9A, the general procedure [E] gives 89.6 g (77% of theory) of product.
HPLC (Method 1): Rt=4.36 min
MS (ESI-pos): m/z=456 (M+H)+
Example 12A
Methyl (2E)-3-{5-cyano-2-[(triphenylphosphoranylidene)amino]phenyl}propenoate
Figure USRE049698-20231017-C00022
Starting with 1.24 g (4.60 mmol) of the amine compound from Example 5A, the general procedure
[E] gives 2.12 g (92% of theory) of product.
HPLC (Method 1): Rt=4.42 min
MS (ESI-pos): m/z=463 (M+H)+
General Procedure [F]: Synthesis of Phenylpiperazines by the Buchwald-Hartwig Reaction
To prepare for the reaction, the reaction flask is thoroughly dried by heating under high vacuum and vented with argon. 1.0 equivalent of the bromoaryl compound and 6.0 equivalents of piperazine in absolute toluene are initially charged in the flask (0.2-0.3M solution of the bromo compound). 0.01 equivalent of tris(dibenzylideneacetone)dipalladium and 0.03 equivalent of BINAP are then added. The reaction mixture is stirred under reflux for 16 h. The mixture is then extracted once with water, the organic phase is extracted twice with 1N hydrochloric acid and the aqueous phase is adjusted to pH 8 using 1N aqueous sodium hydroxide solution and extracted three times with dichloromethane. The combined organic phases are dried over sodium sulphate and filtered, the solvent is removed under reduced pressure and the product is dried under high vacuum overnight.
Example 13A
N-(4-Fluoro-3-methylphenyl)piperazine
Figure USRE049698-20231017-C00023
Starting with 5.0 g (26.5 mmol) of 4-fluoro-3-methyl-1-bromobenzene, the general procedure [F] gives 4.52 g (83% of theory) of product.
HPLC (Method 1): Rt=3.54 min
MS (ESI pos): m/z=195 (M+H)+
Example 14A
N-(4-Fluorophenyl)-3-methylpiperazine
Figure USRE049698-20231017-C00024
Starting with 1.0 g (5.71 mmol) of 4-fluoro-3-methyl-1-bromobenzene, the general procedure [F] gives 0.57 g (49% of theory) of product.
HPLC (Method 1): Rt=3.37 min
MS (DCI pos): m/z=195 (M+H)+
Example 15A
1-(3-Fluorophenyl)piperazine
Figure USRE049698-20231017-C00025
1 g (5.71 mmol) of 3-fluorobromobenzene and 2.95 g (34.29 mmol) of piperazine are dissolved in 20 ml of toluene, and 0.77 g (8 mmol) of sodium tert-butoxide is added. In the presence of 0.11 g (0.17 mmol) of BINAP and 0.05 g (0.06 mmol) of tris(dibenzylideneacetone)dipalladium, the mixture is then stirred under reflux overnight. After cooling, ethyl acetate is added and the mixture is washed with water. The mixture is then extracted with 1N hydrochloric acid, and the aqueous phase is washed with ethyl acetate. The pH is adjusted to 8-9 and the mixture is then extracted with dichloromethane. The organic phase is dried over magnesium sulphate and the solvent is removed, giving the target compound.
Yield: 0.8 g (78% of theory)
HPLC (Method 1): Rt=3.4 min
MS (ESI-pos): m/z=181 (M+H)+
Example 16A
1-(3,4-Difluorophenyl)piperazine
Figure USRE049698-20231017-C00026
In 100 ml of toluene, 5 g (25.91 mmol) of 3,4-difluorobromobenzene, 13.39 g (155.45 mmol) of piperazine, 3.49 g (36.27 mmol) of sodium tert-butoxide, 0.24 g (0.26 mmol) of tris(dibenzylidene-acetone)dipalladium and 0.48 g (0.78 mmol) of BINAP are stirred under reflux overnight. Ethyl acetate is added, the mixture is then washed with water and the organic phase is extracted with 1N hydrochloric acid. The aqueous phase is then washed with ethyl acetate and subsequently adjusted to pH 8. Using dichloromethane, the product is extracted from the aqueous phase. The extract is then dried over magnesium sulphate, the solvent is removed and the target compound is dried under reduced pressure.
Yield: 3.85 g (75% of theory)
HPLC (Method 1): Rt=3.4 min
MS (DCI): m/z=199 (M+H)+
Example 17A
2-Isocyanato-1-methoxy-4-(trifluoromethyl)benzene
Figure USRE049698-20231017-C00027
3 g (15.69 mmol) of 2-methoxy-5-trifluoromethylaniline are dissolved in 100 ml of dichloromethane, and 6.73 g (31.39 mmol) of 1,8-bis(dimethylamino)naphthalene are added. At 0-5° C., 2.24 g (11.3 mmol) of trichloromethyl chloroformate, dissolved in 50 ml of dichloromethane, are added dropwise, and the mixture is stirred at 0° C. for 30 min and then at room temperature for 60 min. At 0° C., the mixture is washed with 1N hydrochloric acid, ice-water and sodium bicarbonate solution. Drying over magnesium sulphate and removal of the solvent by distillation gives the product. The isocyanate is then used for the subsequent reactions without further purification.
Yield: 3.00 g (88% of theory)
Example 18A
Methyl (2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]imino}methylene)amino]-phenyl}-2-propenoate
Figure USRE049698-20231017-C00028
5.0 g (10.98 mmol) of methyl (2E)-3-{3-fluoro-2-[(triphenylphosphoranylidene)amino]phenyl}-2-propenoate (Example 10A) are initially charged in 50 ml of dichloromethane, and the mixture is stirred with 2.5 g (11.53 mmol) of 2-isocyanato-1-methoxy-4-(trifluoromethyl)benzene (Example 17A) at room temperature overnight. The solvent is removed by distillation and the product is then purified by chromatography on silica gel (isohexane/dichloromethane 2:1; 1:1) and recrystallized from isohexane.
Yield: 2.69 g (62% of theory)
HPLC (Method 1): Rt=5.6 min
MS (ESI-pos): m/z=395 (M+H)+
General Procedure [G]: Reaction of the Iminophosphorane with an Isocyanate and Subsequent Reaction with an Amine to Give the Dihydroquinazoline Derivative
1.0 equivalent of the iminophosphorane is dissolved in 20 ml of dichloromethane (0.1-0.2M solution). 1.05 equivalents of a substituted isocyanate are then added, and the mixture is stirred at RT until the reaction has ended. The reaction is monitored by TLC or by analytical HPLC.
1.0 equivalent of amine and a spatula tip of silica gel are then added to the resulting solution of the carbodiimide and dichloromethane, and the mixture is stirred at room temperature until the reaction has gone to completion. After the reaction has ended (reaction is monitored by TLC or HPLC), the mixture is concentrated and purified by preparative HPLC on an RP phase.
In certain cases, the NMR shows the presence of a varying proportion of non-cyclized reaction product. In those cases, the mixture of cyclized and non-cyclized product is taken up in dioxane, a spatula tip of silica gel is added and the mixture is stirred under reflux for 30 min to 16 h. The silica gel is filtered off and the solution is used for further reactions.
If it is intended to produce enantiomerically pure compounds, the chromatographic separation is carried out at this stage.
Example 19A
Methyl {8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00029
Starting with 92.5 mg (0.2 mmol) of the iminophosphorane from Example 10A, the general procedure [G] gives 50 mg (45% of theory) of product.
HPLC (Method 1): Rt=4.81 min
Example 20A
Methyl {8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00030
This compound is obtained as enantiomer A following the separation of enantiomers of 3.84 g of Example 19A (715 mg, 14% of theory).
HPLC (Method 1): Rt=4.81 min
MS (ESI-pos): m/z=544.9 (M+H)+
Example 21A
Methyl {6-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00031
Starting with 100 mg (0.28 mmol) of the iminophosphorane from Example 1A 11A, the general procedure [G] gives 58 mg (39% of theory) of product.
HPLC (Method 1): Rt=4.80 min
Example 22A
Methyl {6-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00032
This compound is obtained as enantiomer A following the separation of enantiomers of 832 mg of Example 21A (368 mg, 17% of theory).
HPLC (Method 1): Rt=4.77 min
MS (ESI-pos): m/z=544.9 (M+H)+
Example 23A
Methyl {8-fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00033
Starting with 93 mg (0.2 mmol) of the iminophosphorane from Example 10A, the general procedure [G] gives 43 mg (39% of theory) of product.
HPLC (Method 1): Rt=4.80 min
MS (ESI-pos): m/z=541.0 (M+H)+
Example 24A
Methyl {8-fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00034
This compound is obtained as enantiomer A following the separation of enantiomers of 3.31 g of Example 23A (1.18 g, 22% of theory).
HPLC (Method 1): Rt=4.80 min
MS (ESI-pos): m/z=541.0 (M+H)+
Example 25A
Methyl {8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00035
Starting with 93 mg (0.2 mmol) of the iminophosphorane from Example 10A, the general procedure [G] gives 51 mg (45% of theory) of product.
HPLC (Method 1): Rt=4.62 min
MS (ESI-pos): m/z=556.7 (M+H)+
Example 26A
Methyl {8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00036
This compound is obtained as enantiomer A following the separation of enantiomers of 5.11 g of Example 25A (0.49 g, 9% of theory).
HPLC (Method 1): Rt=4.71 min
MS (ESI-pos): m/z=556.8 (M+H)+
Example 27A
Methyl {8-fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-methoxy-3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00037
Starting with 1.0 g (2.2 mmol) of the iminophosphorane from Example 10A, 500 mg (2.31 mmol) of 2-isocyanato-1-methoxy-4-(trifluoromethyl)benzene (Example 17A) and 427 mg (2.2 mmol) of the phenylpiperazine from Example 13A, 1.03 g (79% of theory) of crude product are obtained following filtration through silica gel (cyclohexane/ethyl acetate 2:1 (v/v)). This product is reacted further without further purification.
LC-MS (Method 3): Rt=2.55 min, 2.66 min
MS (ESI-pos): m/z=589.3 (M+H)+
Example 28A
Methyl {8-fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-methoxy-3-methylphenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00038
Starting with 0.60 g (1.76 mmol) of the iminophosphorane from Example 10A, 376 mg (2.31 mmol) of 2-methoxy-5-methylphenyl isocyanate and 342 mg (1.76 mmol) of the phenylpiperazine from Example 13A, 183 mg (16% of theory) of product are obtained after purification by preparative HPLC.
HPLC (Method 1): Rt=4.77 min
MS (ESI-pos): m/z=535.2 (M+H)+
Example 29A
Methyl {8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[6-methoxy-3-chlorophenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00039
Starting with 1.0 g (2.2 mmol) of the iminophosphorane from Example 10A, 423 mg (2.31 mmol) of 2-methoxy-5-chlorophenyl isocyanate and 396 mg (2.2 mmol) of 4-fluorophenylpiperazine, 621 mg (52% of theory) of product are obtained after purification by preparative HPLC.
HPLC (Method 1): Rt=4.75 min
MS (ESI-pos): m/z=541.2 (M+H)+
Example 30A
Methyl {8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00040
550 mg (1.39 mmol) of methyl (2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methylene)amino]phenyl}-2-propenoate (Example 18A) and 251 mg (1.39 mmol) of 1-(4-fluorophenyl)piperazine are stirred in the presence of a spatula tip of silica gel in 15 ml of dichloromethane for 1 hour. After 90 hours of stirring under reflux, the product is purified by chromatography on silica gel (dichloromethane, dichloromethane/ethyl acetate 10:1).
Yield: 769 mg (96% of theory)
HPLC (Method 1): Rt=4.8 min
MS (ESI-pos): m/z=575 (M+H)+
Example 31A
Methyl {8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00041
700 mg (1.78 mmol) of methyl (2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methylene)amino]phenyl}-2-propenoate (Example 18A), 341 mg (1.78 mmol) of 1-(3-methoxyphenyl)piperazine and a spatula tip of silica gel are stirred in 20 ml of dichloromethane at room temperature for one hour and then under reflux for 35 hours. The target compound is obtained after purification on silica gel (dichloromethane, dichloromethane/ethyl acetate 10:1).
Yield: 1012 mg (97% of theory)
HPLC (Method 6): Rt=4.8 min
MS (ESI-pos): m/z=587 (M+H)+
Example 32A
Methyl {8-fluoro-2-[4-(3,4-difluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00042

700 mg (1.78 mmol) of methyl (2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methylene)amino]phenyl}-2-propenoate (Example 18A), 352 mg (1.78 mmol) of 1-(3,4-difluorophenyl)piperazine (Example 16A) and a spatula tip of silica gel are stirred in 20 ml of dichloromethane at room temperature for 1 hour and then under reflux for 20 hours. The target compound is then purified by chromatography on silica gel (dichloromethane, dichloromethane/ethyl acetate 10:1).
Yield: 1027 mg (97% of theory)
HPLC (Method 1): Rt=4.8 min
MS (ESI-pos): m/z=593 (M+H)+
Example 33A
Methyl {8-fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00043
11.5 g (29.16 mmol) of methyl (2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methylene)amino]phenyl}-2-propenoate (Example 18A), 5.14 g (29.16 mmol) of 1-(3-methylphenyl)piperazine and a spatula tip of silica gel are stirred in 300 ml of dichloromethane at room temperature for 1 hour and then under reflux for 20 hours. The product is obtained after chromatography on silica gel (dichloromethane, dichloromethane/ethyl acetate 10:1, 5:1).
Yield: 15.8 g (95% of theory)
HPLC (Method 1): Rt=4.8 min
MS (ESI-pos): m/z=571 (M+H)+
Example 34A
Methyl {8-fluoro-2-[4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00044
100 mg (0.25 mmol) of methyl (2E)-3-{3-fluoro-2-[({[2-methoxy-5-(trifluoromethyl)phenyl]-imino}methylene)amino]phenyl}-2-propenoate (Example 18A), 45.7 mg (0.25 mmol) of 1-(3-fluorophenyl)piperazine (Example 15A) and a spatula tip of silica gel are stirred in 15 ml of dichloromethane at room temperature for 1 hour and then under reflux for 20 hours. The target compound is obtained after chromatography on silica gel (dichloromethane, dichloromethane/ethyl acetate 10:1).
Yield: 139.2 mg (96% of theory)
HPLC (Method 1): Rt=4.8 min
MS (ESI-pos): m/z=575 (M)+ (M+H)+
Example 35A
Methyl {8-fluoro-2-[4-(3-chlorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00045
Starting with 93 mg (0.2 mmol) of the iminophosphorane from Example 10A, the general procedure [G] gives 51 mg (45% of theory) of product.
LC-MS (Method 3): Rt=4.78 min
MS (ESI-pos): m/z=561 (M+H)+
Example 36A
Methyl {8-fluoro-2-[4-(1,3-benzodioxol-5-yl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00046
Starting with 4.19 g (9.2 mmol) of the iminophosphorane from Example 10A, the general procedure [G] gives 3.67 g (70% of theory) of product.
HPLC (Method 1): Rt=4.67 min
MS (ESI-pos): m/z=571 (M+H)+
Example 37A
Methyl 4-amino-3-[(1E)-3-tert-butoxy-3-oxoprop-1-en-1-yl]benzoate
Figure USRE049698-20231017-C00047
Starting with 25.0 g (90.2 mmol) of methyl 4-amino-3-iodobenzoate, the general procedure [A] gives 24.3 g (88% of theory) of product.
HPLC (Method 1): Rt=4.71 min
MS (DCI-pos): m/z=295 (M+NH4)+
Example 38A
Methyl (2E)-3-(4-cyano-2-nitrophenyl)-2-propenoate
Figure USRE049698-20231017-C00048
Starting with 3.00 g (17.0 mmol) of 4-cyano-2-nitrobenzaldehyde, the general procedure [B] and recrystallization from methanol gives 2.51 g (63% of theory) of product.
HPLC (Method 1): Rt=4.06 min
MS (ESI-pos): m/z=233 (M+H)+
Example 39A
Methyl 3-[2-amino-7-cyanophenyl]propenoate
Figure USRE049698-20231017-C00049
Starting with 1.0 g (4.31 mmol) of the nitro compound from Example 38A, the general procedure [D] (but without boiling over activated carbon) gives 793 mg (89% of theory) of product.
HPLC (Method 1): Rt=3.99 min
Example 40A
Methyl (2E)-3-{6-cyano-2-[(triphenylphosphoranylidene)amino]phenyl}propenoate
Figure USRE049698-20231017-C00050
Starting with 0.75 g (3.71 mmol) of the amine compound from Example 39A, the general procedure [E] gives 1.09 g (62% of theory) of product.
HPLC (Method 1): Rt=4.30 min
MS (ESI-pos): m/z=463 (M+H)+
Example 41A
Methyl 3-[(1E)-3-tert-butoxy-3-oxoprop-1-en-1-yl]-4-[(triphenylphosphoranylidene)amino]-benzoate
Figure USRE049698-20231017-C00051
Starting with 19.0 g (68.5 mmol) of the amine compound from Example 37A, the general procedure [E] gives 31.4 g (85% of theory) of product.
HPLC (Method 1): Rt=4.69 min
MS (ESI-pos): m/z=538 (M+H)+
Example 42A
Methyl {8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00052
This compound is obtained as enantiomer A by separating the racemate from Example 30A chromatographically according to Method 15 in to into the enantiomers. Starting with 231 g of racemate, 120 g of the target product, which is directly reacted further, are obtained.
MS (ESI-pos): m/z=575 (M+H)+
Example 43A
Methyl {8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00053
The compound is obtained as enantiomer A by separating the racemate from Example 31A chromatographically according to Method 15 into the enantiomers. Starting with 231 g of racemate, 111 g (48% of theory) of the target product are obtained.
MS (ESI-pos): m/z=587 (M+H)+
Example 44A
Methyl {6-cyano-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00054
Starting with 400 mg (0.6 mmol) of the iminophosphorane from Example 12A, the general procedure [G] gives 166 mg (48% of theory) of product.
HPLC (Method 1): Rt=4.65 min
MS (ESI-pos): m/z=552 (M+H)+
Example 45A
Methyl {7-cyano-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00055
Starting with 1.0 g (2.16 mmol) of the iminophosphorane from Example 40A, the general procedure [G] gives 1.07 g (98% of theory) of product.
HPLC (Method 1): Rt=4.72 min
MS (ESI-pos): m/z=552 (M+H)+
Example 46A
Methyl 4-(2-tert-butoxy-2-oxoethyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)-phenyl]-3,4-dihydroquinazoline-6-carboxylate
Figure USRE049698-20231017-C00056
Starting with 4.2 g (9.3 mmol) of the iminophosphorane from Example 41A, the general procedure [G] gives 3.9 g (51% of theory) of product.
HPLC (Method 1): Rt=5.03 min
MS (ESI-pos): m/z=627 (M+H)+
Example 47A
Methyl {8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate
Figure USRE049698-20231017-C00057
This compound is obtained as enantiomer A following the separation of enantiomers of 3.5 g of Example 46A (1.4 mg, 20% of theory).
HPLC (Method 1): Rt=4.91 min
MS (ESI-pos): m/z=627 (M+H)+
Example 48A
4-(2-tert-Butoxy-2-oxoethyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-6-carboxylic acid
Figure USRE049698-20231017-C00058
1.3 g (2.0 mmol) of the methyl carboxylate from Example 47A are dissolved in 12 ml of dioxane, 2.4 ml of an aqueous 1N solution of potassium hydroxide are added and the mixture is stirred at 60° C. for 5 hours. The pH is adjusted to pH=4 using an aqueous 1N solution of hydrochloric acid and the reaction mixture is concentrated and purified by preparative HPLC. This gives 580 mg (48% of theory) of the product.
HPLC (Method 1): Rt=4.85 min
MS (ESI-pos): m/z=613 (M+H)+
Example 49A
Tert-butyl {6-(aminocarbonyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetate
Figure USRE049698-20231017-C00059
560 mg (0.9 mmol) of the carboxylic acid from Example 48A, 2.6 mmol of aluminium chloride, 1.1 mmol of 1-hydroxy-1H-benzotriazole hydrate and 1.1 mmol of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide are suspended in DMF. 2.6 mmol of N,N-diisopropylamine are added, and the mixture is stirred at room temperature for 16 hours. 20 ml of ethyl acetate are added to the reaction mixture, which is then washed with a saturated aqueous sodium bicarbonate solution and a saturated aqueous sodium chloride solution. The combined aqueous phases are adjusted to pH=8 and extracted with ethyl acetate. The combined organic phases are finally washed with a saturated aqueous sodium chloride solution, dried over sodium sulphate and concentrated. This gives 548 mg (97% of theory) of product.
HPLC (Method 1): Rt=4.73 min
MS (ESI-pos): m/z=612 (M+H)+
Examples 50A to 112A 111A of Table 1 can be prepared from the corresponding starting materials using the general procedures [A] to [G].
TABLE 1
Example R HPLC MS ESIpos.
No. Structure [min] method [M + H]+
50A
Figure USRE049698-20231017-C00060
4.53 1 561 [M + H − HCl]+
51A
Figure USRE049698-20231017-C00061
4.22 1 556 [M + H − HCl]+
52A
Figure USRE049698-20231017-C00062
4.36 1 552 [M + H − HCl]+
53A
Figure USRE049698-20231017-C00063
4.37 1 572 [M + H − HCl]+
54A
Figure USRE049698-20231017-C00064
4.54 1 549 [M + H − HCl]+
55A
Figure USRE049698-20231017-C00065
4.27 1 568 [M + H − HCl]+
56A
Figure USRE049698-20231017-C00066
4.30 1 538
57A
Figure USRE049698-20231017-C00067
4.28 1 518
58A
Figure USRE049698-20231017-C00068
4.41 1 538
59A
Figure USRE049698-20231017-C00069
4.82 1 557
60A
Figure USRE049698-20231017-C00070
4.61 1 549 [M + H − HCl]+
61A
Figure USRE049698-20231017-C00071
4.89 1 517
62A
Figure USRE049698-20231017-C00072
4.81 6 605
63A
Figure USRE049698-20231017-C00073
4.60 6 591
64A
Figure USRE049698-20231017-C00074
4.85 6 591
65A
Figure USRE049698-20231017-C00075
4.92 6 609
66A
Figure USRE049698-20231017-C00076
4.83 1 603
67A
Figure USRE049698-20231017-C00077
4.78 1 587
68A
Figure USRE049698-20231017-C00078
5.13 1 563
69A
Figure USRE049698-20231017-C00079
4.76 1 563
70A
Figure USRE049698-20231017-C00080
4.81 1 581
71A
Figure USRE049698-20231017-C00081
5.21 1 581
72A
Figure USRE049698-20231017-C00082
5.21 1 575
73A
Figure USRE049698-20231017-C00083
4.98 1 559
74A
Figure USRE049698-20231017-C00084
4.86 1 591
75A
Figure USRE049698-20231017-C00085
4.86 6 593
76A
Figure USRE049698-20231017-C00086
4.94 1 547
77A
Figure USRE049698-20231017-C00087
4.82 1 539
78A
Figure USRE049698-20231017-C00088
4.92 1 589
79A
Figure USRE049698-20231017-C00089
4.57 1 582
80A
Figure USRE049698-20231017-C00090
2.38 3 495
81A
Figure USRE049698-20231017-C00091
1.95 9 491
82A
Figure USRE049698-20231017-C00092
1.97 9 507
83A
Figure USRE049698-20231017-C00093
1.93 9 511
84A
Figure USRE049698-20231017-C00094
1.90 9 487
85A
Figure USRE049698-20231017-C00095
4.87 1 541
86A
Figure USRE049698-20231017-C00096
4.91 1 561
87A
Figure USRE049698-20231017-C00097
4.76 1 557
88A
Figure USRE049698-20231017-C00098
4.65 1 552
89A
Figure USRE049698-20231017-C00099
4.77 1 568
90A
Figure USRE049698-20231017-C00100
4.62 1 564
91A
Figure USRE049698-20231017-C00101
5.00 1 609
92A
Figure USRE049698-20231017-C00102
4.70 1 563
93A
Figure USRE049698-20231017-C00103
577
94A
Figure USRE049698-20231017-C00104
4.74 1 545
95A
Figure USRE049698-20231017-C00105
4.90 1 605
96A
Figure USRE049698-20231017-C00106
4.83 1 563
97A
Figure USRE049698-20231017-C00107
4.82 1 537
98A
Figure USRE049698-20231017-C00108
4.90 1 557
99A
Figure USRE049698-20231017-C00109
4.81 1 553
100A 
Figure USRE049698-20231017-C00110
101A 
Figure USRE049698-20231017-C00111
4.78 1 521
102A 
Figure USRE049698-20231017-C00112
4.73 1 517
103A 
Figure USRE049698-20231017-C00113
3.10 16  533
104A 
Figure USRE049698-20231017-C00114
2.75 17  555
105A 
Figure USRE049698-20231017-C00115
2.95 17  555
106A 
Figure USRE049698-20231017-C00116
4.74 1 545
107A 
Figure USRE049698-20231017-C00117
4.93 1 541
108A 
Figure USRE049698-20231017-C00118
5.08 1 575
109A 
Figure USRE049698-20231017-C00119
4.88 1 563
110A 
Figure USRE049698-20231017-C00120
4.54 1 531 [M + H − HCl]+
111A 
Figure USRE049698-20231017-C00121
4.54 1 571 [M + H − HCl]+
WORKING EXAMPLES
General Procedure [H]: Hydrolysis of the Quinazolylacetic Acid Esters
1.0 equivalent of the quinazolyl ester are dissolved in dioxane, and 5.0 equivalents of 1N aqueous sodium hydroxide solution are added. The mixture is stirred at 80° C. for 16 hours, and after the reaction has ended (the reaction is monitored by analytical HPLC) the mixture is concentrated. The residue is then taken up in water and adjusted to pH 5 using 1N hydrochloric acid. The resulting precipitate is filtered off, washed with a little water and diethyl ether and dried at room temperature under high vacuum. Alternatively, the precipitate can be filtered off through an Extrelute cartridge, then washed with ethyl acetate, followed by concentration of the filtrate. If the purity of the product is not high enough, the product is purified either by preparative HPLC on an RP phase (Method 2 or Method 5) or on silica gel using mixtures of cyclohexane/ethyl acetate.
Example 1
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00122
Starting with 37 mg (0.07 mmol) of the methyl ester from Example 19A, the general procedure [H] gives 29 mg (80% of theory) of product.
HPLC (Method 1): Rt=4.49 min
MS (ESI-pos): m/z=530.7 (M+H)+
1H NMR (400 MHz, CD3CN): δ [ppm]=7.59 (s, 1H); 7.45 (t, 1H); 7.37 (t, 2H); 7.02-6.95 (m, 3H); 6.93-6.85 (m, 4H); 5.24 (dd, 1H); 2.98 (db, 4H); 2.91 (db, 4H); 2.73 (dd, 1H); 2.54 (dd, 1H).
Example 2
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00123
Starting with 695 mg (1.27 mmol) of the methyl ester from Example 20A, the general procedure [H] gives 488 mg (64% of theory) of product.
HPLC (Method 1): Rt=4.59 min
MS (ESI-pos): m/z=530.8 (M+H)+
1H NMR (400 MHz, CD3CN): δ [ppm]=7.60 (s, 1H); 7.47-7.40 (m, 3H); 7.03-6.86 (m, 7H); 5.26-5.23 (m, 1H); 3.60-3.52 (m, 4H); 2.99-2.90 (m, 4H); 2.75 (dd, 1H); 2.56 (dd, 1H).
Example 3
{8-Fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00124
Starting with 34 mg (0.06 mmol) of the methyl ester from Example 23A, the general procedure [H] gives 30 mg (90% of theory) of product.
HPLC (Method 1): Rt=4.56 min
MS (ESI-pos): m/z=526.9 (M+H)+
1H NMR (200 MHz, DMSO-d6): δ [ppm]=7.64 (s, 1H); 7.53 (t, 1H); 7.44-7.34 (m, 2H); 7.11-6.90 (m, 3H); 6.72-6.59 (m, 4H); 5.33-5.25 (m, 1H); 3.52 (db, 4H); 3.02 (db, 4H); 2.69-2.55 (m, 2H, partially obscured by DMSO signal); 2.23 (s, 3H).
Example 4
{8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00125
Starting with 36 mg (0.07 mmol) of the methyl ester from Example 25A, the general procedure [H] and chromatography (Method 2) give 28 mg (77% of theory) of product.
HPLC (Method 1): Rt=4.46 min
MS (ESI-pos): m/z=542.9 (M+H)+
1H NMR (200 MHz, DMSO-d6): δ [ppm]=7.67 (s, 1H); 7.54 (t, 1H); 7.45-7.38 (m, 2H); 7.14-6.94 (m, 3H); 6.51-6.35 (m, 4H); 5.35-5.25 (m, 1H); 3.69 (s, 3H); 3.50 (db, 4H); 3.06 (db, 4H); 2.58-2.52 (m, 2H).
Example 5
{8-Fluoro-2-[4-(3-chlorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00126
Starting with 38 mg (0.07 mmol) of the methyl ester from Example 35A, the general procedure [H] gives 25 mg (66% of theory) of product.
HPLC (Method 1): Rt=4.64 min
MS (ESI-pos): m/z=546.9 (M+H)+
1H NMR (200 MHz, DMSO dd6): δ [ppm]=7.66 (s, 1H); 7.52 (t, 1H); 7.38 (dd, 2H); 7.20 (t, 1H); 7.10-6.78 (m, 6H); 5.33-5.26 (m, 1H); 3.51 (db, 4H); 3.11 (db, 4H); 2.61-2.55 (m, 2H).
Example 6
{8-Fluoro-2-[4-(1,3-benzodioxol-5-yl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00127
Starting with 173 mg (0.30 mmol) of the methyl ester from Example 36A, the general procedure [H] gives 79 mg (46% of theory) of product.
HPLC (Method 1): Rt=4.44 min
MS (ESI-pos): m/z=557.2 (M+H)+
1H NMR (300 MHz, CDCl3): δ [ppm]=7.47 (s, 1H); 7.42-7.34 (m, 3H); 7.03-6.89 (m, 2H); 6.79 (d, 1H); 6.64 (d, 1H); 6.41 (d, 1H); 6.22 (dd, 1H); 5.87 (s, 2H); 5.20-5.15 (m, 1H); 3.59 (sb, 3H); 2.94-2.85 (m, 5H); 2.59 (dd, 1H).
Example 7
{6-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00128
Starting with 42 mg (0.08 mmol) of the methyl ester from Example 21A, the general procedure [H] gives 34 mg (76% of theory) of product.
HPLC (Method 1): Rt=4.63 min
MS (ESI-pos): m/z=530.9 (M+H)+
Example 8
{6-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
Figure USRE049698-20231017-C00129
Starting with 350 mg (0.64 mmol) of the ester from Example 22A, the general procedure [H] gives 284 mg (83% of theory) of product.
HPLC (Method 1): Rt=4.53 min
MS (ESI-pos): m/z=530.8 (M+H−HCl)+
1H NMR (400 MHz, CD3CN): δ [ppm]=7.62 (s, 1H); 7.51-7.48 (m, 1H); 7.43-7.41 (d, 1H); 7.26-7.23 (m, 1H); 7.04-6.95 (m, 2H); 6.91-6.85 (m, 3H); 5.23 (dd, 1H); 3.55 (sb, 3H); 3.02-2.99 (m, 1H); 2.94 (sb, 4H); 2.80 (dd, 1H).
Example 9
{8-Fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
Figure USRE049698-20231017-C00130
Starting with 1.10 g (1.93 mmol) of the ester from Example 24A, the general procedure [H] gives 1.04 g (91% of theory) of product. Following the separation of enantiomers by Method 4, the product is obtained as enantiomer A.
HPLC (Method 1): Rt=4.68 min
MS (ESI-pos): m/z=526.9 (M+H−HCl)+
1H NMR (400 MHz, CD3CN): δ [ppm]=7.61 (s, 1H); 7.49-7.38 (m, 3H); 7.10-6.89 (m, 4H); 6.71-6.65 (m, 3H); 5.26 (dd, 1H); 3.60-3.52 (m, 4H); 3.03-2.95 (m, 4H); 2.76 (dd, 1H); 2.57 (dd, 1H); 2.25 (s, 3H).
Example 10
{8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
Figure USRE049698-20231017-C00131
Starting with 437 mg (0.79 mmol) of the ester from Example 26A, the general procedure [H] gives 344 mg (72% of theory) of product.
HPLC (Method 1): Rt=4.48 min
MS (ESI-pos): m/z=543.0 (M+H−HCl)+
1H NMR (400 MHz, CD3CN): δ [ppm]=7.61 (s, 1H); 7.49-7.38 (m, 3H); 7.14-6.89 (m, 4H); 6.47-6.39 (m, 3H); 5.26 (dd, 1H); 3.72 (s, 1H); 3.60-3.54 (m, 4H); 3.07-3.00 (m, 4H); 2.77 (dd, 1H); 2.57 (dd, 1H).
Example 11
{8-Fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-methoxy-3-(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
Figure USRE049698-20231017-C00132
Starting with 1.03 g (1.75 mmol) of the crude product of the ester from Example 27A, the general procedure [H] and chromatography according to Method 5 followed by dissolution of the product in methanol/1N hydrochloric acid and re-evaporation of the solvent give 283 mg (22% of theory) of hydrochloride.
HPLC (Method 1): Rt=4.58 min
MS (ESI-pos): m/z=575.2 (M+H−HCl)+
1H NMR (400 MHz, CD3CN): δ [ppm]=8.17 (s, 0.66H); 7.69 (d, 1H); 7.55-7.30 (m, 1H); 7.27-7.24 (m, 2H); 7.16 (d, 0.6H); 7.09-7.04 (m, 2H); 5.33-5.27, 5.12-5.06 (2×m, 1H); 4.08-3.35 (m, 4H); 3.69 (s, 3H); 3.30-3.22 (m, 1H); 2.80-2.76 (m, 1H); 2.25 (s, 3H).
Example 12
{8-Fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-methoxy-3-(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
Figure USRE049698-20231017-C00133
Prior to the separation of enantiomers, 268 mg of the hydrochloride from Example 11 are taken up in dichloromethane, and the organic phase is extracted twice with saturated sodium bicarbonate solution. The combined aqueous phases are extracted once with dichloromethane, the combined organic phases are dried over sodium sulphate and filtered and the solvent is removed under reduced pressure. This gives 204 mg (86% of theory) of the free base. Using this material, separation of enantiomers (Method 4), re-purification by preparative HPLC (Method 5) and subsequent dissolution of the product in methanol/1N hydrochloric acid and re-evaporation of the solvent gives 80 mg (78% of theory) of enantiomer A.
HPLC (Method 6): Rt=4.66 min
MS (ESI-pos): m/z=575.2 (M+H−HCl)+
1H NMR (400 MHz, CD3CN): δ [ppm]=8.17 (s, 0.66H); 7.69 (d, 1H); 7.45-7.30 (m, 1H); 7.24 (d, 2H); 7.15 (d, 0.7H); 7.08-7.01 (m, 2H); 5.32-5.27, 5.11-5.07 (2×m, 1H); 4.06-3.50 (m, 4H); 3.68 (s, 3H); 3.33-3.24 (m, 1H); 2.77-2.72 (m, 1H); 2.24, 2.23 (2×s, 3H).
Example 13
{8-Fluoro-2-[4-(4-fluoro-3-methylphenyl)-1-piperazinyl]-3-[6-methoxy-3-methylphenyl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
Figure USRE049698-20231017-C00134
Starting with 183 mg (0.34 mmol) of the crude product of the ester from Example 28A, the general procedure [H] and chromatography according to Method 5 followed by dissolution of the product in methanol/1N hydrochloric acid and re-evaporation of the solvent give 135 mg (67% of theory) of hydrochloride.
HPLC (Method 1): Rt=4.67 min
MS (ESI-pos): m/z=521.2 (M+H−HCl)+
1H NMR (400 MHz, CD3CN): δ [ppm]=7.69-7.42 (m, 4H); 7.25-7.06 (m, 5H); 6.93-6.78 (m, 1H); 5.24-5.21, 5.06-5.03 (2×m, 1H); 4.00-3.35 (m, 8H); 3.21-3.08 (m, 1H); 3.01-2.77 (m, 1H); 2.34, 2.20 (2×s, 3H); 2.26 (s, 3H).
Example 14
{8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00135
At room temperature, 179.6 mg (4.49 mmol) of sodium hydroxide are added to 878 mg (1.5 mmol) of methyl {8-fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 31A) in 40 ml of dioxane, and the mixture is stirred at 50° C. for 2 hours. The pH is then adjusted to 4-5. The product is filtered off, washed with water and dried under reduced pressure.
Yield: 801 mg (93% of theory)
HPLC (Method 1): Rt=4.5 min
MS (ESI-pos): m/z=573 (M+H)+
Example 15
{8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00136
After separation of enantiomers (Method 11) of 500 mg of racemate (Example 14), the crude product is purified by chromatography on silica gel and then dissolved in 1N aqueous sodium hydroxide solution and extracted with diethyl ether. Following acidification with 1N hydrochloric acid, the product is filtered off and dried under reduced pressure.
Yield: 105 mg (21% of theory)
MS (ESI-pos): m/z=573 (M+H)+
1H NMR (300 MHz, DMSO-d6): δ [ppm]=2.4-2.5 (m, 1H); 2.7-3.1 (m, 5H); 3.3-3.6 (m, 4H); 3.7 (s, 3H); 3.7-3.9 (sb, 3H); 4.8-5.05 (sb, 1H); 6.3-6.4 (m, 2H); 6.4-6.5 (m, 1H); 6.8-7.65 (m, 6H); 12.5 (sb, 1H).
Alternatively, the target product is obtained by reacting the enantiomerically pure ester from Example 43A according to the general procedure [H]. Starting with 111 g (0.19 mol) of ester, 69 g (63% of theory) of target product are obtained.
Example 16
{8-Fluoro-2-[4-(3,4-difluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00137
In 40 ml of dioxane, 881 mg (1.49 mmol) of methyl {8-fluoro-2-[4-(3,4-difluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 32A) and 178 mg (4.46 mmol) of sodium hydroxide are stirred at 50° C. for 2 hours. Following acidification with 1N hydrochloric acid, the product is filtered off with suction, washed with water and dried under reduced pressure.
Yield: 775 mg (90% of theory)
HPLC (Method 1): Rt=4.5 min
MS (ESI-pos): m/z=579 (M+H)+
Example 17
{8-Fluoro-2-[4-(3,4-difluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00138
Following the separation of enantiomers (Method 12) of 500 mg (0.86 mmol) of racemate (Example 16), the crude product is purified by chromatography on silica gel (dichloromethane, dichloromethane/methanol 20:1, 10:1), dissolved in 1N aqueous sodium hydroxide solution and extracted with diethyl ether. Using 1N hydrochloric acid the aqueous phase is adjusted to pH 4-5, and the product is filtered off, washed with water and dried under reduced pressure.
Yield: 86 mg (17% of theory)
MS (ESI-pos): m/z=579 (M+H)+
1H NMR (300 MHz, DMSO-d6): δ [ppm]=2.6-3.1 (m, 6H); 3.25-3.6 (m, 4H); 3.75 (sb, 3H); 4.85 (sb, 1H); 6.6-6.7 (m, 1H); 6.7-7.7 (m, 9H); 12.5 (sb, 1H).
Example 18
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00139
In 800 ml of dioxane, 15 g (26.11 mmol) of methyl {8-fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 30A) and 3.13 g (78.32 mmol) of sodium hydroxide are stirred at 50° C. for 4 hours. Following distillative removal of the solvent, the residue is dissolved in 500 ml of water and acidified and the precipitate is filtered off with suction. The product is washed with water and dried under reduced pressure.
Yield: 14.5 g (99% of theory)
HPLC (Method 1): Rt=4.5 min
MS (ESI-pos): m/z=561 (M+H)+
Example 19
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00140
14.2 g (25.33 mmol) of racemate (Example 18) are separated (Method 13). The crude product is dissolved in 250 ml of 0.5N sodium hydroxide solution and then purified by extraction with diethyl ether. After acidification of the aqueous phase with hydrochloric acid, the product is filtered off, washed with water and dried under reduced pressure.
Yield: 5.85 g (41% of theory)
MS (ESI-pos): m/z=561 (M+H)+
HPLC (Method 1): Rt=4.5 min
1H NMR (400 MHz, DMSO-D6): δ [ppm]=2.6-3.0 (m, 6H); 3.3-3.6 (m, 4H); 3.6-4.0 (sb, 3H); 4.8-5.2 (sb, 1H); 6.7-7.75 (m, 10H); 12.2-12.8 (sb, 1H).
Alternatively, the target product is obtained by reacting the enantiomerically pure ester from Example 42A according to the general procedure [11] [H]. Starting with 120 g (0.21 mol) of ester, 96 g (81% of theory) of target product are obtained.
Example 20
{8-Fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00141
In 40 ml of dioxane, 892 mg (1.56 mmol) of methyl {8-fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 33A) and 187.6 mg (4.69 mmol) of sodium hydroxide are stirred at 50° C. for 2 hours. Following removal of the solvent, the residue is taken up in water and adjusted to pH 4-5 using 1N hydrochloric acid. The product is filtered off and then washed with water and dried under reduced pressure.
Yield: 788 mg (91% of theory)
MS (ESI-pos): m/z=557 (M+H)+
HPLC (Method 6): Rt=4.5 min
Example 21
{8-Fluoro-2-[4-(3-methylphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00142
The separation of enantiomers (Method 13) is carried out using 500 mg (0.9 mmol) of racemate (Example 20). The crude product is then dissolved in 1N aqueous sodium hydroxide solution, the solution is extracted with diethyl ether and the aqueous phase is adjusted to pH 4-5 using 1N hydrochloric acid. The product is filtered off with suction, washed with water and dried under reduced pressure.
Yield: 104 mg (21% of theory)
MS (ESI-pos): m/z=557 (M+H)+
1H NMR (400 MHz, DMSO d6)(400 MHz, DMSO-d6): δ [ppm]=2.2 (sb, 3H); 2.35-2.5 (m, 1H); 2.6-3.1 (m, 5H); 3.3-3.6 (m, 4H); 3.8 (sb, 3H); 4.9 (sb, 1H); 6.5-6.7 (m, 3H); 6.8-7.7 (m, 7H); 12.6 (sb, 1H).
Example 22
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[6-methoxy-3-chlorophenyl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
Figure USRE049698-20231017-C00143
Starting with 621 mg (1.15 mmol) of the ester from Example 29A, the general procedure [H] and purification by preparative HPLC (Method 5) and coevaporation with methanol/N methanol/1N hydrochloric acid give 330 mg (51% of theory) of product.
HPLC (Method 1): Rt=4.58 min
MS (ESI-pos): m/z=527.0 (M+H−HCl)+
Example 23
{8-Fluoro-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[6-methoxy-3-chlorophenyl]-3,4-dihydro-4-quinazolinyl}acetic acid hydrochloride
Figure USRE049698-20231017-C00144
Starting with 320 mg (0.06 mmol) of the racemate from Example 22, chromatographic separation of enantiomers (Method 4) and subsequent dissolution of the product in methanol/1N hydrochloric acid and re-evaporation of the solvent give 174 mg (50% of theory) of hydrochloride.
HPLC (Method 1): Rt=4.51 min
MS (ESI-pos): m/z=527.1 (M+H−HCl)+
1H NMR (400 MHz, CD3CN): δ [ppm]=7.29 (dd, 1H); 7.19-7.11 (m, 2H); 7.01-6.94 (m, 4H); 6.87-6.83 (m, 2H); 5.08 (t, 1H); 3.67 (s, 3H); 3.56 (s, 4H); 3.03-2.92 (m, 5H); 2.72 (dd, 1H).
Example 24
{8-Fluoro-2-[4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00145
In 15 ml of dioxane, 117 mg (0.2 mmol) of methyl {8-fluoro-2-[4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetate (Example 34A) are mixed with 0.61 ml of 1N aqueous sodium hydroxide solution, and the mixture is stirred at 50° C. for 3 hours. After removal of the solvent, the residue is taken up in water and the mixture is adjusted to pH 34 3-4 using 1N hydrochloric acid. The precipitate is filtered off with suction, washed with water and dried under reduced pressure.
Yield: 76 mg (67% of theory)
HPLC (Method 1): Rt=4.6 min
MS (ESI-pos): m/z=561 (M+H)+
Example 25
{8-Fluoro-2-[4-(3-fluorophenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00146
52 mg (0.09 mmol) of the racemate (Example 24) are separated into the enantiomers (Method 13). The crude product is then purified by chromatography on silica gel (acetic acid, dichloromethane/methanol 10:1) and dried under reduced pressure.
Yield: 12.3 mg (24% of theory)
LC-MS (Method 7): Rt=2.50 min
MS (ESI-pos): m/z=561 (M+H)+
1H NMR (400 MHz, DMSO-d6): δ [ppm]=2.35-2.5 (m, 1H); 2.7-3.1 (m, 5H); 3.3-3.6 (m, 4H); 3.8 (sb, 3H); 4.8-4.9 (m, 1H); 6.45-6.6 (m, 1H); 6.6-6.7 (m, 2H); 6.8-6.9 (m, 2H); 6.98-7.1 (m, 1H); 7.1-7.6 (m, 4H); 12.4 (sb, 1H).
Examples 26 to 34 and 36 to 89 of Table 2 can be prepared from the corresponding starting materials using the general procedures [A] to [H], and Example 35 can be prepared as described below in Table 2.
TABLE 2
Molecular Starting
Example weight material R4 HPLC
No. Structure [g/mol] Example [min] Method MS
26
Figure USRE049698-20231017-C00147
597.0 50A 4.53  1 561 [M + H − HCl]+
27
Figure USRE049698-20231017-C00148
592.0 51A 4.22  1 556 [M + H − HCl]+
28
Figure USRE049698-20231017-C00149
588.0 52A 4.36  1 552 [M + H − HCl]+
29
Figure USRE049698-20231017-C00150
608.4 53A 4.37  1 572 [M + H − HCl]+
30
Figure USRE049698-20231017-C00151
584.9 54A 4.54  1 548 [M + H − HCl]+
31
Figure USRE049698-20231017-C00152
604.0 55A 4.27  1 568 [M + H − HCl]+
32
Figure USRE049698-20231017-C00153
537.5 56A 4.30  1 538 [M + H − HCl]+
33
Figure USRE049698-20231017-C00154
517.5 57A 4.28  1 518 [M + H − HCl]+
34
Figure USRE049698-20231017-C00155
537.5 58A 4.41  1 538 [M + H − HCl]+
35
Figure USRE049698-20231017-C00156
565.0 89 4.47  1 529 [M + H]+
36
Figure USRE049698-20231017-C00157
584.9 60A 4.61  1 549 [M + H]+
37
Figure USRE049698-20231017-C00158
502.6 61A 4.6   1 503 [M + H]+
38
Figure USRE049698-20231017-C00159
590.6 62A 4.6   6 591 [M + H]+
39
Figure USRE049698-20231017-C00160
590.6 63A 4.53  1 591 [M + H]+
40
Figure USRE049698-20231017-C00161
576.6 64A 4.5   6 577 [M + H]+
41
Figure USRE049698-20231017-C00162
594.6 65A 4.5   6 595 [M + H]+
42
Figure USRE049698-20231017-C00163
588.6 66A 4.4   6 589 [M + H]+
43
Figure USRE049698-20231017-C00164
572.6 67A 4.5   6 573 [M + H]+
44
Figure USRE049698-20231017-C00165
548.6 68A 4.9   1 549 [M + H]+
45
Figure USRE049698-20231017-C00166
548.5 69A 4.67  1 549 [M + H]+
46
Figure USRE049698-20231017-C00167
566.5 70A 4.60  1 567 [M + H]+
47
Figure USRE049698-20231017-C00168
566.6 71A 4.9   1 567 [M + H]+
48
Figure USRE049698-20231017-C00169
560.7 72A 4.8   1 561 [M + H]+
49
Figure USRE049698-20231017-C00170
544.7 73A 5.0   1 545 [M + H]+
50
Figure USRE049698-20231017-C00171
576.6 74A 4.6   1 577 [M + H]+
51
Figure USRE049698-20231017-C00172
578.5 75A 4.7   1 579 [M + H]+
52
Figure USRE049698-20231017-C00173
532.6 76A 4.6   1 561 [M + H]+
53
Figure USRE049698-20231017-C00174
524.5 77A 4.5   1 525 [M + H]+
54
Figure USRE049698-20231017-C00175
574.6 78A 4.7   1 561 [M + H]+
55
Figure USRE049698-20231017-C00176
567.6 79A 4.3   1 568 [M + H]+
56
Figure USRE049698-20231017-C00177
494.5 80A 2.77 10 495 [M + H]+
57
Figure USRE049698-20231017-C00178
490.6 81A 1.94  9 491 [M + H]+
58
Figure USRE049698-20231017-C00179
507.0 82A 1.97  9 507 [M + H]+
59
Figure USRE049698-20231017-C00180
511.0 83A 1.93  9 511 [M + H]+
60
Figure USRE049698-20231017-C00181
486.6 84A 1.90  9 487 [M + H]+
61
Figure USRE049698-20231017-C00182
526.5 85A 4.69  1 527 [M + H]+
62
Figure USRE049698-20231017-C00183
545.0 86A 3.57  8 547 [M + H]+
63
Figure USRE049698-20231017-C00184
542.5 87A 3.37  8 543 [M + H]+
64
Figure USRE049698-20231017-C00185
574.0 88A 4.43  1 538 [M + H − HCl]+
65
Figure USRE049698-20231017-C00186
590.4 89A 4.58  1 554 [M + H − HCl]+
66
Figure USRE049698-20231017-C00187
586.0 90A 4.41  1 550 [M + H − HCl]+
67
Figure USRE049698-20231017-C00188
594.5 91A 4.82  1 595 [M + H]+
68
Figure USRE049698-20231017-C00189
548.5 92A 4.06  1 549 [M + H]+
69
Figure USRE049698-20231017-C00190
562.5 93A 4.74  1 563 [M + H]+
70
Figure USRE049698-20231017-C00191
530.5 94A 4.62  1 531 [M + H]+
71
Figure USRE049698-20231017-C00192
591.5 95A 4.76  1 591 [M + H]+
72
Figure USRE049698-20231017-C00193
548.5 96A 4.63  1 549 [M + H]+
73
Figure USRE049698-20231017-C00194
523.0 97A 4.65  1 523 [M + H]+
74
Figure USRE049698-20231017-C00195
543.4 98A 4.67  6 543 [M + H]+
75
Figure USRE049698-20231017-C00196
539.0 99A 4.56  6 539 [M + H]+
76
Figure USRE049698-20231017-C00197
599.5 100A 4.63  6 523 [M + H − HCl]+
77
Figure USRE049698-20231017-C00198
506.6 101A 4.52  6 507 [M + H]+
78
Figure USRE049698-20231017-C00199
539.0 102A 4.63  6 503 [M + H − HCl]+
79
Figure USRE049698-20231017-C00200
555.0 103A 4.41  6 519 [M + H − HCl]+
80
Figure USRE049698-20231017-C00201
577.5 104A 4.53  6 541 [M + H − HCl]+
81
Figure USRE049698-20231017-C00202
541.0 105A 4.68  1 541 [M + H]+
82
Figure USRE049698-20231017-C00203
537.5 45A 4.52  1 538 [M + H]+
83
Figure USRE049698-20231017-C00204
530.5 106A 4.51  1 531 [M + H]+
84
Figure USRE049698-20231017-C00205
526.5 107A 4.70  1 527 [M + H]+
85
Figure USRE049698-20231017-C00206
583.4 108A 4.61  1 547 [M + H − HCl]+
86
Figure USRE049698-20231017-C00207
585.0 109A 4.82  1 549 [M + H − HCl]+
87
Figure USRE049698-20231017-C00208
530.5 110A 4.54  1 531 [M + H]+
88
Figure USRE049698-20231017-C00209
570.6 111A 4.54  1 571 [M + H]+
89
Figure USRE049698-20231017-C00210
579.0 59A 4.60  1 543 [M + H − HCl]+
Example 35
{2-[4-(4-Fluorophenyl)piperazin-1-yl]-8-hydroxy-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid
Figure USRE049698-20231017-C00211
80 mg (0.14 mmol) of the methyl ether (Example 89) are dissolved in 2 ml of dichloromethane, and 0.41 mmol of a 1M solution of boron tribromide in dichloromethane is added at 0° C. The mixture is stirred at room temperature for 16 hours, a further 0.82 mmol of the boron tribromide solution is added, followed by a further 1.23 mmol after 24 hours. The reaction mixture is stirred at room temperature for 24 hours and then poured onto ice, and 5 ml of a 1N aqueous hydrochloric acid solution are added. The mixture is extracted with 25 ml of ethyl acetate. The organic phase is washed with a saturated aqueous sodium chloride solution, dried over sodium sulphate, concentrated and purified by preparative HPLC. This gives 50 mg (63% of theory) of product.
HPLC (Method 1): Rt=4.47 min
MS (ESI-pos): m/z=529 (M+H−HCl)+
Example 90
{7-Hydroxycarbonyl-2-[4-(4-fluorophenyl)-1-piperazinyl]-3-[5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
Figure USRE049698-20231017-C00212
100 mg (0.16 mmol) of the ester from Example 45A are suspended in semiconcentrated hydrochloric acid, and the reaction mixture is stirred at 90° C. for 42 hours. After cooling, the mixture is adjusted to pH=4 using 20% strength aqueous sodium hydroxide solution and the precipitate that is formed is filtered off, washed with water and dried under reduced pressure.
Yield: 64 mg (66% of theory)
HPLC (Method 1): Rt=4.38 min
MS (ESI-pos): m/z=557 (M+H)+
Example 91
{6-(Aminocarbonyl)-2-[4-(4-fluorophenyl)piperazin-1-yl]-3-[3-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid hydrochloride
Figure USRE049698-20231017-C00213
500 mg (0.8 mmol) of the tert-butyl ester from Example 49A are suspended with 8 ml of a 4M solution of hydrogen chloride in dioxane, and the reaction mixture is stirred at room temperature for 16 hours. The suspension is concentrated and dried under reduced pressure.
Yield: 564 mg (99% of theory)
HPLC (Method 1): Rt=4.25 min
MS (ESI-pos): m/z=556 (M+H−HCl)+
1H NMR (300 MHz, DMSO-D6): δ [ppm]=12.94 (brs, 1H); 8.11 (s, 1H); 8.03-7.95 (m, 2H); 7.92-7.65 (m, 4H); 7.09-6.91 (m, 4H); 5.50 (dd, 1H); 4.38-4.12 (m, 4H); 3.17-3.06 (m, 5H); 2.81 (dd, 1H).
B. Assessment of the Physiological Activity
The in vitro effect of the compounds of the invention can be shown in the following assays:
Anti-HCMV (Anti-Human Cytomegalovirus) Cytopathogenicity Tests
The test compounds are employed as 50 millimolar (mM) solutions in dimethyl sulphoxide (DMSO). Ganciclovir®, Foscarnet® and Cidofovir® are used as reference compounds. After addition of in each case 2 μl of the 50, 5, 0.5 and 0.05 mM DMSO stock solutions to 98 μl portions of cell culture medium in row 2 A-H for duplicate determinations, 1:2 dilutions are carried out with 50 μl portions of medium up to row 11 of the 96-well plate. The wells in rows 1 and 12 each contain 50 μl of medium. In 150 μl of a suspension of 1×104 cells (human prepuce fibroblasts [NHDF]) are pipetted into each of the wells (row 1=cell control) and, in rows 2-12, a mixture of HCMV-infected and uninfected NHDF cells (M.O.I.=0.001-0.002), i.e. 1-2 infected cells per 1000 uninfected cells. Row 12 (without substance) serves as virus control. The final test concentrations are 250-0.0005 μM. The plates are incubated at 37° C./5% CO2 for 6 days, i.e. until all the cells are infected in the virus controls (100% cytopathogenic effect [CPE]). The wells are then fixed and stained by adding a mixture of formalin and Giemsa's dye (30 minutes), washed with double-distilled water and dried in a drying oven at 50° C. The plates are then assessed visually using an overhead microscope (Plaque Multiplier from Technomara).
The following data can be acquired from the test plates:
CC50 (NHDF)=substance concentration in μM at which no visible cytostatic effects on the cells are evident by comparison with the untreated cell control;
EC50 (HCMV)=substance concentration in μM which inhibits the CPE (cytopathic effect) by 50% compared with the untreated virus control;
SI (selectivity index)=CC50 (NHDF)/EC50 (HCMV).
Representative in vitro data for the effects of the compounds of the invention are shown in Table A:
TABLE A
NHDF
Example CC50 HCMV SI
No. [μM] EC50 [μM] HCMV
2 12 0.016 750
9 15 0.02 750
15 31 0.002 15500
19 17 0.002 8947
23 24 0.002 12632
29 47 0.07 671
The suitability of the compounds of the invention for the treatment of HCMV infections can be shown in the following animal model:
HCMV Xenograft Gelfoam® Model
Animals:
3-4-week old female immunodeficient mice (16-18 g), Fox Chase SCID or Fox Chase SCID-NOD or SCID beige, are purchased from commercial breeders (Taconic M+B, Jackson USA). The animals are housed under sterile conditions (including bedding and feed) in isolators.
Virus growing:
Human cytomegalovirus (HCMV), Davis or AD169 strain, is grown in vitro on human embryonic prepuce fibroblasts (NHDF cells). After the NHDF cells have been infected with a multiplicity of infection (M.O.I.) of 0.01-0.03, the virus-infected cells are harvested 5-10 days later and stored in the presence of minimal essential medium (MEM), 10% fetal calf serum (FCS) with 10% DMSO at 40° C. −40° C. After serial ten-fold dilutions of the virus-infected cells, the titer is determined on 24-well plates of confluent NHDF cells after vital staining with Neutral Red.
Preparation of the Sponges, Transplantation, Treatment and Evaluation:
Collagen sponges 1×1×1 cm in size (Gelfoam®; from Peasel & Lorey, order No. 407534; K. T. Chong et al., Abstracts of 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999, p. 439) are initially wetted with phosphate-buffered saline (PBS), the trapped air bubbles are removed by degassing, and then stored in MEM+10% FCS. 1×106 virus-infected NHDF cells (infection with HCMV Davis or HCMV AD169 M.O.I. =0.01) are detached 3 hours after infection and added in a drop of 20 μl of MEM, 10% of FCS, to a moist sponge. About 16 hours later, the infected sponges are incubated with 25 μl of PBS/0.1% BSA/1 mM DTT with 5 ng/μl basic fibroblast growth factor (bFGF). For the transplantation, the immunodeficient mice are anaesthetized with Avertin or a ketamine/xylazine/azepromazine mixture, the fur on the back is removed using a shaver, the epidermis is opened 1-2 cm, unstressed and the moist sponges are transplanted under the dorsal skin. The surgical wound is closed with tissue glue. 6 hours after the transplantation, the mice can be treated for the first time (on the day of the operation, there is one treatment). The next days, over a period of 8 days, the mice are treated with substance orally three times a day (7.00 h and 14.00 h and 19.00 h), two times a day (8.00 h and 18.00 h) or once a day (14.00 h). The daily dose is, for example 3 or 10 or 30 or 60 or 100 mg/kg of body weight, the volume administered is 10 ml/kg of body weight. The substances are formulated in the form of a 0.5% strength Tylose suspension with 2% DMSO or a 0.5% strength Tylose suspension. 9 days after transplantation and 16 hours after the last administration of substance, the animals are painlessly sacrificed and the sponge is removed. The virus-infected cells are released from the sponge by collagenase digestion (330 U/1.5 ml) and stored in the presence of MEM, 10% fetal calf serum, 10% DMSO at −140° C. Evaluation takes place after serial ten-fold dilutions of the virus-infected cells by determining the titer on 24-well plates of confluent NHDF cells after vital staining with Neutral Red. The number of infected cells or infectious virus particles (infectious centre assay) after the substance treatment compared with the placebo-treated control is determined.
CYP Inhibition Assay
To investigate the mechanism-based (irreversible) inhibition of CYP3A4, different concentrations of the test substance are incubated with human liver microsomes (2 mg/ml of microsomal protein) in potassium phosphate buffer pH 7.4 with addition of an NADPH-generating system (NADP+, glucose 6-phosphate, glucose 6-phosphate dehydrogenase) at 37° C. At various points of time, 2 aliquots are taken from the incubation.
The first aliquot is incubated 1:50 in a new incubation solution (phosphate buffer, NADPH-generating system and 10 μM of Midazolam) at 37° C. for a further 10 min. The incubation is then stopped using acetonitrile on ice, the protein is pelleted in a centrifuge at 15 000 g and the supernatant is analysed for formation of 1′-hydroxyimidazolam using standard HPLC/MS methods.
The second aliquot is stopped using acetonitrile on ice and analysed for remaining test substance using HPLC/UV/MS.
The two sets of analytical data are determined for irreversible-inhibition-typical parameters (kinact, Ki and partition ratio r), and using these data, the test substance is evaluated (cf. A. Madan, et al., in A. D. Rodrigues (ed.) “Drug-Drug Interaction” in “Drugs and the Pharmaceutical Science”, Vol. 116, ISBN 0-8247-0283.2, Marcel Dekker Inc., New York, 2002.).
C. Exemplary Embodiments of Pharmaceutical Compositions
The compounds of the invention can be converted into pharmaceutical preparations in the following ways:
Tablet:
Composition:
100 mg of the compound of Example 1, 50 mg of lactose (monohydrate), 50 mg of corn starch (native), 10 mg of polyvinylpyrrolidone (PVP 25) (from BASF, Ludwigshafen, Germany) and 2 mg of magnesium stearate.
Tablet weight 212 mg. Diameter 8 mm, radius of curvature 12 mm.
Production:
The mixture of active ingredient, lactose and starch is granulated with a 5% strength solution (m/m) of the PVP in water. The granules are then dried and mixed with the magnesium stearate for 5 min. This mixture is compressed using a conventional tablet press (see above for format of the tablet). A guideline for the compressive force used for the compression is 15 kN.
Suspension which can be Administered Orally:
Composition:
1000 mg of the compound of Example 1, 1000 mg of ethanol (96%), 400 mg of Rhodigel (xanthan gum from FMC, Pennsylvania, USA) and 99 g of water.
10 ml of oral suspension are equivalent to a single dose of 100 mg of the compound of the invention.
Production:
The Rhodigel is suspended in ethanol, and the active ingredient is added to the suspension. The water is added while stirring. The mixture is stirred for about 6 h until the swelling of the Rhodigel is complete.
Solution which can be Administered Intravenously:
Composition:
10-500 mg of the compound of Example 1, 15 g of polyethylene glycol 400 and 250 g of water for injection.
Production:
The compound of Example 1 is dissolved together with polyethylene glycol 400 in the water with stirring. The solution is sterilized by filtration (pore diameter 0.22 μm) and dispensed under aseptic conditions into heat-sterilized infusion bottles. The latter are closed with infusion stoppers and trimmed caps.

Claims (27)

The invention claimed is:
1. A compound of the formula
Figure USRE049698-20231017-C00214
in which
Ar represents aryl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl, amino, alkylamino, aminocarbonyl and nitro,
where alkyl may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of halogen, amino, alkylamino, hydroxyl and aryl,
R1 represents hydrogen, amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro or trifluoromethyl,
R2 represents hydrogen, alkyl, alkoxy, alkylthio, cyano, halogen, nitro or trifluoromethyl,
R3 represents amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro, trifluoromethyl, alkylsulphonyl or alkylaminosulphonyl
R4 represents hydrogen or alkyl,
R5 represents hydrogen or alkyl
or
the radicals R4 and R5 are attached to carbon atoms directly opposing each other in the piperazine ring and form a methylene bridge which is optionally substituted by 1 or 2 methyl groups,
R6 represents alkyl, alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,
R7 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro
and
R8 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,
or a salt, solvate, or solvate of a salt thereof.
2. A compound according to claim 1, wherein
Ar represents phenyl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of C1-C6-alkyl, C1-C6-alkoxy, carboxyl, C1-C6-alkylcarbonyl, C1-C6-alkoxycarbonyl, trifluoromethyl, fluorine, chlorine, bromine, cyano, hydroxyl, amino, C1-C6-alkylamino and nitro,
R1 represents hydrogen, C1-C3-alkyl, C1-C3-alkoxy, C1-C3-alkylthio, fluorine or chlorine,
R2 represents hydrogen, C1-C3-alkyl, C1-C3-alkoxy, C1-C3-alkylthio, fluorine or chlorine,
R3 represents C1-C4-alkyl, cyano, fluorine, chlorine, nitro, trifluoromethyl or C1-C3-alkylsulphonyl,
R4 represents hydrogen or methyl,
R5 represents hydrogen,
R6 represents C1-C3-alkyl, C1-C3-alkoxy, carboxyl, aminocarbonyl, trifluoromethyl, fluorine, chlorine, cyano, hydroxyl or nitro,
R7 represents hydrogen, C1-C3-alkyl, C1-C3-alkoxy, fluorine, chlorine, cyano or hydroxyl
and
R8 represents hydrogen, C1-C3-alkyl, C1-C3-alkoxy, fluorine, chlorine, cyano or hydroxyl.
3. A compound according to claim 1 wherein
Ar represents phenyl which may be substituted by 1 or 2 substituents, where the substituents are selected independently of one another from the group consisting of methyl, methoxy, fluorine and chlorine,
R1 represents hydrogen, methyl, methoxy, methylthio, fluorine or chlorine,
R2 represents hydrogen,
R3 represents methyl, isopropyl, tert-butyl, cyano, fluorine, chlorine, nitro or trifluoromethyl,
R4 represents hydrogen,
R5 represents hydrogen,
R6 represents aminocarbonyl, fluorine, chlorine, cyano or hydroxyl,
R7 represents hydrogen
and
R8 represents hydrogen, fluorine or chlorine.
4. A compound according to claim 1, wherein R1 represents hydrogen, methyl, methoxy or fluorine.
5. A compound according to claim 1, wherein R1 represents methoxy.
6. A compound according to claim 1, wherein R1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring.
7. A compound according to claim 1, wherein R2 represents hydrogen.
8. A compound according to claim 1, wherein R3 represents trifluoromethyl, chlorine, methyl, isopropyl or tert-butyl.
9. A compound according to claim 1, wherein R3 represents trifluoromethyl, chlorine or methyl.
10. A compound according to claim 1, wherein R1 is attached to the phenyl ring via the position ortho to the point of attachment of the phenyl ring and R3 is attached to the phenyl ring via the position meta to the point of attachment of the phenyl ring, which position is opposite to that of R1.
11. A compound according to claim 1, wherein R4 and R5 represent hydrogen.
12. A compound according to claim 1, wherein R6 represents fluorine.
13. A compound according to claim 1, wherein R7 represents hydrogen.
14. A compound according to claim 1, wherein R8 represents hydrogen, methyl or fluorine.
15. A compound according to claim 1, wherein Ar represents phenyl which may be substituted by 1 or 2 substituents, where the substituents are selected independently of one another from the group consisting of methyl, methoxy, fluorine and chlorine.
16. A process for preparing a compound of the formula (I) according to claim 1, wherein a compound of the formula
Figure USRE049698-20231017-C00215
in which
Ar, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined in claim 1
and
R9 represents alkyl selected from the group consisting of methyl, ethyl, and tert-butyl,
is reacted with a base or an acid.
17. A medicament comprising a compound according to claim 1 in combination with an inert non-toxic pharmaceutically acceptable auxiliary.
18. A method for treating infection by Herpes viridae in humans and animals by administering an antivirally effective amount of at least one compound according to claim 1, or a medicament according to claim 17.
19. The method according to claim 18, wherein the Heprpes viridae is selected form the group consisting of cytomegalovirus (CMV) and human cytomegalovirus (HCMV) or another representative of the group of the Herpes viridae.
20. A process for preparing a compound of formula (I) or a salt, solvate, or solvate of a salt thereof
Figure USRE049698-20231017-C00216
in which
Ar represents aryl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl, amino, alkylamino, aminocarbonyl and nitro, where alkyl may be substituted by 1 to 3 substituents,
where the substituents are selected independently of one another from the group consisting of halogen, amino, alkylamino, hydroxyl and aryl,
R1 represents hydrogen, amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro or trifluoromethyl,
R2 represents hydrogen, alkyl, alkoxy, alkylthio, cyano, halogen, nitro or trifluoromethyl,
R3 represents amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro, trifluoromethyl, alkylsulphonyl or alkylaminosulphonyl,
R4 represents hydrogen or alkyl,
R5 represents hydrogen or alkyl
or
the radicals R4 and R5 are attached to carbon atoms directly opposing each other in the piperazine ring and form a methylene bridge which is optionally substituted by 1 or 2 methyl groups,
R6 represents alkyl, alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,
R7 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro, and
R8 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,
said process comprising:
(a) reacting a compound of formula (III)
Figure USRE049698-20231017-C00217
wherein R6, R7, and R8 are as defined above and R9 is methyl or ethyl, in a two-step reaction initially with a compound of formula (IV)
Figure USRE049698-20231017-C00218
in which R1, R2 and R3 are as defined above, and then with a compound of formula (V)
Figure USRE049698-20231017-C00219
in which Ar, R4 and R5 are as defined above,
to obtain a compound of formula II
Figure USRE049698-20231017-C00220
in which
Ar, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined above, and
R9 is methyl or ethyl; and
(b) reacting the compound of formula (II) with a base in an inert solvent wherein the base is an alkali metal hydroxide or alkali metal carbonate, and the inert solvent is an ether or alcohol.
21. The process according to claim 20, wherein said base is sodium hydroxide, lithium hydroxide, potassium hydroxide, caesium carbonate, sodium carbonate or potassium carbonate.
22. The process according to claim 20, wherein said base is sodium hydroxide in water.
23. The process according to claim 20, wherein said inert solvent is 1,2-dimethoxyethane, dioxane, tetrahydrofuran, glycol dimethyl ether, diethylene glycol dimethyl ether, methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol, or mixtures thereof.
24. The process according to claim 20, wherein said inert solvent is dioxane or tetrahydrofuran.
25. A process for preparing a compound of formula (I) or a salt, solvate, or solvate of a salt thereof
Figure USRE049698-20231017-C00221
in which
Ar represents aryl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl, amino, alkylamino, aminocarbonyl and nitro, where alkyl may be substituted by 1 to 3 substituents,
where the substituents are selected independently of one another from the group consisting of halogen, amino, alkylamino, hydroxyl and aryl,
R1 represents hydrogen, amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro or trifluoromethyl,
R2 represents hydrogen, alkyl, alkoxy, alkylthio, cyano, halogen, nitro or trifluoromethyl,
R3 represents amino, alkyl, alkoxy, alkylamino, alkylthio, cyano, halogen, nitro, trifluoromethyl, alkylsulphonyl or alkylaminosulphonyl,
R4 represents hydrogen or alkyl,
R5 represents hydrogen or alkyl
or
the radicals R4 and R5 are attached to carbon atoms directly opposing each other in the piperazine ring and form a methylene bridge which is optionally substituted by 1 or 2 methyl groups,
R6 represents alkyl, alkoxy, alkylthio, formyl, carboxyl, aminocarbonyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,
R7 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro, and
R8 represents hydrogen, alkyl, alkoxy, alkylthio, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl or nitro,
said process comprising:
(a) reacting a compound of formula (III)
Figure USRE049698-20231017-C00222
wherein R6, R7, and R8 are as defined above and R9 is methyl or ethyl, in a two-step reaction initially with a compound of formula (IV)
Figure USRE049698-20231017-C00223
in which R1, R2 and R3 are as defined above, and then with a compound of formula (V)
Figure USRE049698-20231017-C00224
in which Ar, R4 and R5 are as defined above,
to obtain a compound of formula II
Figure USRE049698-20231017-C00225
in which
Ar, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined above, and
R9 is tert-butyl, and
(b) reacting a compound of formula (II) with an acid in an inert solvent.
26. The process according to claim 25, wherein the reaction is carried out in a temperature range of from 0° C. to 40° C. at atmospheric pressure.
27. The process according to claim 25, wherein the acid is hydrogen chloride in dioxane, hydrogen bromide in acetic acid, or trifluoroacetic acid in methylene chloride.
US16/934,363 2003-02-05 2020-07-21 Substituted dihydroquinazolines Expired - Lifetime USRE49698E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/934,363 USRE49698E1 (en) 2003-02-05 2020-07-21 Substituted dihydroquinazolines

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE10319612A DE10319612A1 (en) 2003-05-02 2003-05-02 Substituted dihydroquinazolines
DE10319612 2003-05-02
US10/832,109 US7196086B2 (en) 2003-05-02 2004-04-26 Substituted dihydroquinazolines
US14/682,512 USRE46791E1 (en) 2003-05-02 2015-04-09 Substituted dihydroquinazolines
US201815955254A 2018-04-17 2018-04-17
US16/934,363 USRE49698E1 (en) 2003-02-05 2020-07-21 Substituted dihydroquinazolines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/832,109 Reissue US7196086B2 (en) 2003-02-05 2004-04-26 Substituted dihydroquinazolines

Publications (1)

Publication Number Publication Date
USRE49698E1 true USRE49698E1 (en) 2023-10-17

Family

ID=33305099

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/832,109 Ceased US7196086B2 (en) 2003-02-05 2004-04-26 Substituted dihydroquinazolines
US11/728,896 Active 2027-04-26 US8513255B2 (en) 2003-05-02 2007-03-26 Substituted dihydroquinazolines
US14/682,512 Active 2028-11-18 USRE46791E1 (en) 2003-02-05 2015-04-09 Substituted dihydroquinazolines
US16/934,363 Expired - Lifetime USRE49698E1 (en) 2003-02-05 2020-07-21 Substituted dihydroquinazolines

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US10/832,109 Ceased US7196086B2 (en) 2003-02-05 2004-04-26 Substituted dihydroquinazolines
US11/728,896 Active 2027-04-26 US8513255B2 (en) 2003-05-02 2007-03-26 Substituted dihydroquinazolines
US14/682,512 Active 2028-11-18 USRE46791E1 (en) 2003-02-05 2015-04-09 Substituted dihydroquinazolines

Country Status (39)

Country Link
US (4) US7196086B2 (en)
EP (1) EP1622880B3 (en)
JP (1) JP4733631B2 (en)
KR (1) KR100927063B1 (en)
CN (1) CN100393706C (en)
AR (1) AR044078A1 (en)
AT (1) ATE355280T1 (en)
AU (1) AU2004233978B2 (en)
BR (1) BRPI0410029B8 (en)
CA (1) CA2524069C (en)
CL (1) CL2004000930A1 (en)
CO (1) CO5700764A2 (en)
CY (2) CY1106476T1 (en)
DE (2) DE10319612A1 (en)
DK (1) DK1622880T6 (en)
EC (1) ECSP056138A (en)
EG (1) EG25273A (en)
ES (1) ES2284007T7 (en)
FR (1) FR18C1029I2 (en)
HK (1) HK1092463A1 (en)
HN (1) HN2004000146A (en)
HU (2) HUS1800018I1 (en)
IL (1) IL171513A (en)
MA (1) MA27794A1 (en)
MX (1) MXPA05011707A (en)
MY (1) MY144616A (en)
NL (1) NL300933I2 (en)
NO (2) NO333265B3 (en)
NZ (1) NZ543317A (en)
PE (1) PE20050145A1 (en)
PL (1) PL1622880T6 (en)
PT (1) PT1622880E (en)
RU (1) RU2360912C2 (en)
SI (1) SI1622880T1 (en)
TW (1) TWI335912B (en)
UA (1) UA82519C2 (en)
UY (1) UY28294A1 (en)
WO (1) WO2004096778A1 (en)
ZA (1) ZA200508710B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (en) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituted dihydroquinazolines
DE10305785A1 (en) * 2003-02-12 2004-08-26 Bayer Healthcare Ag New 2-(2-phenylpiperanyl-3-phenyl-dihydroquinazolinyl)-acetic acid derivatives, useful as antiviral agents, especially effective against human cytomegalovirus infections
DE10320780A1 (en) 2003-05-09 2005-01-20 Bayer Healthcare Ag Heterocyclyl-substituted dihydroquinazolines
DE10352499A1 (en) 2003-11-11 2005-06-09 Bayer Healthcare Ag Substituted dihydroquinazolines II
DE102004022672A1 (en) * 2004-05-07 2005-11-24 Bayer Healthcare Ag Substituted azachinazolines
DE102005027517A1 (en) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Process for the preparation of dihydroquinazolines
DE102011101446A1 (en) * 2011-05-10 2012-11-15 Aicuris Gmbh & Co. Kg Production of Dense Bodies (DB)
DE102012101673A1 (en) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salts of a dihydroquinazoline derivative
DE102012101680A1 (en) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmaceutical preparation containing an antiviral dihydroquinazoline derivative
DE102012101659A1 (en) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salts of a dihydroquinazoline derivative
AU2014283231B2 (en) * 2013-06-19 2017-12-07 Aicuris Anti-Infective Cures Gmbh Amorphous Letermovir and solid pharmaceutical formulations thereof for oral administration
WO2015088931A1 (en) * 2013-12-12 2015-06-18 Merck Sharp & Dohme Corp. Process for making substituted quinazoline compounds
US10392353B2 (en) * 2015-11-24 2019-08-27 Merck Sharp & Dohme Corp. Processes for making substituted quinazoline compounds using hydrogen bonding catalysts
US10851112B2 (en) 2016-08-08 2020-12-01 Medshine Discovery Inc. Anti-HCMV virus compound
US11174270B2 (en) 2018-02-08 2021-11-16 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method thereof
EP3527209A1 (en) * 2018-02-16 2019-08-21 UCB Biopharma SPRL Pharmaceutical 6,5 heterobicyclic ring derivatives
US11072610B2 (en) 2018-09-12 2021-07-27 Novartis Ag Antiviral pyridopyrazinedione compounds
WO2021061898A1 (en) 2019-09-26 2021-04-01 Novartis Ag Antiviral pyrazolopyridinone compounds
UY39099A (en) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2 - [(4S) -8-FLUORO-2- [4- (3-METOXIFENIL) PIPERAZIN-1-IL] -3- [2-METOXI-5- (TRIFLUOROMETIL) FENIL] -4H-QUINAZOLIN-4-IL ] SODIUM ACETATE AND PHARMACEUTICAL COMPOSITIONS THEREOF
AR121440A1 (en) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg A METHOD OF PREPARING 2-[(4S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN-1-IL]-3-[2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL]-4H- QUINAZOLIN-4-IL] SODIUM ACETATE MONOHYDRATE, SAID COMPOUND AND THE USE THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS
AR121439A1 (en) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg A METHOD FOR PRODUCING A CRYSTALLINE FORM OF 2-[(4S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN-1-IL]-3-[2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL] -4H-QUINAZOLIN-4-IL]SODIUM ACETATE TRIHYDRATE
AR121438A1 (en) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[(4S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN-1-IL]-3-[2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL]-4H ACETATE -QUINAZOLIN-4-IL] AND SODIUM IONS
AR121437A1 (en) 2020-02-27 2022-06-08 Aic246 Gmbh & Co Kg 2-[(4S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN-1-IL]-3-[2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL]-4H- POTASSIUM SALT QUINAZOLIN-4-IL]ACETIC
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
US20230312485A1 (en) 2020-08-17 2023-10-05 Lupin Limited A precipitation process for amorphous letermovir
CN115403528A (en) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 Process for preparing amorphous 3, 4-dihydroquinazoline derivatives
CN114031560B (en) * 2021-11-16 2022-10-04 山东诚创蓝海医药科技有限公司 Preparation method of letermovir sodium salt
AR128035A1 (en) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[(4S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN-1-IL]-3-[2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL]-4H ACETATE -QUINAZOLIN-4-IL] AND POTASSIUM IONS
WO2023185597A1 (en) * 2022-04-01 2023-10-05 上海迪赛诺化学制药有限公司 Letermovir intermediate and preparation method therefor
CN115322157B (en) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 Letermopevir intermediate compound, preparation method and application thereof
CN117229223A (en) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 Heterocyclic derivative, and pharmaceutical composition and application thereof

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (en) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazoline derivatives and medicaments containing them
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1999037291A2 (en) 1998-01-23 1999-07-29 Bayer Aktiengesellschaft Utilization of substituted sulfonamides as antiviral agents and novel substances
WO1999041253A1 (en) 1998-02-17 1999-08-19 Tularik Inc. Anti-viral pyrimidine derivatives
WO2001002350A2 (en) 1999-06-30 2001-01-11 Bayer Aktiengesellschaft Novel amino sulfonamides and amido sulfonamides as antiviral agents
EP1172361A1 (en) 1999-04-19 2002-01-16 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
US20020019397A1 (en) 2000-07-12 2002-02-14 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
EP1201765A2 (en) 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
WO2002085869A1 (en) 2001-04-19 2002-10-31 Bayer Aktiengesellschaft Arylsulfonamides as antiviral agents
US20030216401A1 (en) 2000-07-31 2003-11-20 Jonathan Mark Bentley Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles
WO2004041790A1 (en) 2002-11-08 2004-05-21 Bayer Healthcare Ag Substituted quinazolines as antiviral agents, especially against cytomegaloviruses
WO2004072048A1 (en) 2003-02-12 2004-08-26 Bayer Healthcare Ag 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazoline-4-yl) acetic acids as anti-viral agents, especially against cytomegalo viruses
WO2004096778A1 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Substituted dihydrochinazolines having antiviral properties
WO2004099212A1 (en) 2003-05-09 2004-11-18 Bayer Healthcare Ag Heterocyclyl-substituted dihydroquinazolines and use thereof as an antiviral agent
EP1568695A1 (en) 2004-02-24 2005-08-31 Korea Institute of Science and Technology 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same
US20060211683A1 (en) * 2005-01-25 2006-09-21 Prolexys Pharmaceuticals Inc. Erastin and erastin binding proteins, and uses thereof
US7115636B2 (en) 2001-08-06 2006-10-03 Bayer Healthcare Ag Hetrocyclic aryl sulphonamides
US20080132515A1 (en) 2004-05-07 2008-06-05 Bayer Healthcare Ag Substituted Azaquinazolines Having an Antiviral Action
US20090221822A1 (en) 2005-06-15 2009-09-03 Bayer Healthcare Ag Process for the Preparation of Dihydroquinazolines
US20100280021A1 (en) 2005-07-21 2010-11-04 Steven Joseph Berthel Pyridopyrimidine protein tyrosine phosphatase inhibitors
US8314113B2 (en) 2003-11-11 2012-11-20 Aicuris Gmbh & Co. Kg Substituted dihydroquinazolines II
US8318761B2 (en) 2006-03-03 2012-11-27 Aicuris Gmbh & Co. Kg Substituted arylsulfonamides as antiviral agents
US20150038514A1 (en) 2012-02-29 2015-02-05 Aicuris Gmbh & Co. Kg Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents
US20150133461A1 (en) 2012-02-29 2015-05-14 Aicuris Gmbh & Co. Kg Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
US20160145216A1 (en) 2013-06-19 2016-05-26 Aicuris Anti-Infective Cures Gmbh Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
US9512085B2 (en) 2012-02-29 2016-12-06 Aicuris Gmbh & Co. Kg Salts of a dihydroquinazoline derivative

Patent Citations (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320347A1 (en) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazoline derivatives and medicaments containing them
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1999037291A2 (en) 1998-01-23 1999-07-29 Bayer Aktiengesellschaft Utilization of substituted sulfonamides as antiviral agents and novel substances
WO1999041253A1 (en) 1998-02-17 1999-08-19 Tularik Inc. Anti-viral pyrimidine derivatives
EP1172361A1 (en) 1999-04-19 2002-01-16 Shionogi & Co., Ltd. Sulfonamide derivatives having oxadiazole rings
WO2001002350A2 (en) 1999-06-30 2001-01-11 Bayer Aktiengesellschaft Novel amino sulfonamides and amido sulfonamides as antiviral agents
US20020019397A1 (en) 2000-07-12 2002-02-14 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US20030216401A1 (en) 2000-07-31 2003-11-20 Jonathan Mark Bentley Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles
EP1201765A2 (en) 2000-10-16 2002-05-02 Axxima Pharmaceuticals Aktiengesellschaft Cellular kinases involved in cytomegalovirus infection and their inhibition
WO2002085869A1 (en) 2001-04-19 2002-10-31 Bayer Aktiengesellschaft Arylsulfonamides as antiviral agents
US7115612B2 (en) 2001-04-19 2006-10-03 Bayer Aktiengesellschaft Arylsulfonamides as antiviral agents
US7115636B2 (en) 2001-08-06 2006-10-03 Bayer Healthcare Ag Hetrocyclic aryl sulphonamides
WO2004041790A1 (en) 2002-11-08 2004-05-21 Bayer Healthcare Ag Substituted quinazolines as antiviral agents, especially against cytomegaloviruses
US7709491B2 (en) 2002-11-08 2010-05-04 Bayer Schering Pharma Aktiengesellschaft Substituted quinazolines as antiviral agents, especially against cytomegaloviruses
US20060235032A1 (en) 2002-11-08 2006-10-19 Tobias Wunberg Substituted quinazolines as antiviral agents, especially against cytomegaloviruses
WO2004072048A1 (en) 2003-02-12 2004-08-26 Bayer Healthcare Ag 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazoline-4-yl) acetic acids as anti-viral agents, especially against cytomegalo viruses
US7960387B2 (en) 2003-02-12 2011-06-14 Bayer Schering Pharma Aktiengesellschaft 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses
US20070066622A1 (en) 2003-02-12 2007-03-22 Tobias Wunberg 2-(3-Phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses
US20070191387A1 (en) 2003-05-02 2007-08-16 Bayer Healthcare Ag Substituted dihydroquinazolines
USRE46791E1 (en) 2003-05-02 2018-04-17 Aicuris Anti-Infective Cures Gmbh Substituted dihydroquinazolines
US8513255B2 (en) 2003-05-02 2013-08-20 AiCuris GmbH + Co. KG. Substituted dihydroquinazolines
WO2004096778A1 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Substituted dihydrochinazolines having antiviral properties
US20050065160A1 (en) 2003-05-02 2005-03-24 Bayer Healthcare Ag Substituted dihydroquinazolines
WO2004099212A1 (en) 2003-05-09 2004-11-18 Bayer Healthcare Ag Heterocyclyl-substituted dihydroquinazolines and use thereof as an antiviral agent
US8343981B2 (en) 2003-05-09 2013-01-01 Aicuris Gmbh & Co. Kg Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents
US8314113B2 (en) 2003-11-11 2012-11-20 Aicuris Gmbh & Co. Kg Substituted dihydroquinazolines II
US7271260B2 (en) 2004-02-24 2007-09-18 Korea Institute Of Science And Technology 3,4-dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same
EP1568695A1 (en) 2004-02-24 2005-08-31 Korea Institute of Science and Technology 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same
US20050197351A1 (en) 2004-02-24 2005-09-08 Yong Sup Lee 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same
US20080132515A1 (en) 2004-05-07 2008-06-05 Bayer Healthcare Ag Substituted Azaquinazolines Having an Antiviral Action
US7662822B2 (en) 2004-05-07 2010-02-16 Bayer Schering Pharma Aktiengesellschaft Substituted azaquinazolines having an antiviral action
US8198282B2 (en) 2004-05-07 2012-06-12 Aicuris Gmbh & Co. Kg Substituted azaquinazolines having an antiviral action
US20060211683A1 (en) * 2005-01-25 2006-09-21 Prolexys Pharmaceuticals Inc. Erastin and erastin binding proteins, and uses thereof
US20090221822A1 (en) 2005-06-15 2009-09-03 Bayer Healthcare Ag Process for the Preparation of Dihydroquinazolines
US8372972B2 (en) 2005-06-15 2013-02-12 Aicuris Gmbh & Co. Kg Process for the preparation of dihydroquinazolines
US8084604B2 (en) 2005-06-15 2011-12-27 Aicuris GmbH & Co., KG Process for the preparation of dihydroquinazolines
US8816075B2 (en) 2005-06-15 2014-08-26 Aicuris Gmbh & Co. Kg Process for the preparation of dihydroquinazolines
US20100280021A1 (en) 2005-07-21 2010-11-04 Steven Joseph Berthel Pyridopyrimidine protein tyrosine phosphatase inhibitors
US8318761B2 (en) 2006-03-03 2012-11-27 Aicuris Gmbh & Co. Kg Substituted arylsulfonamides as antiviral agents
US20150038514A1 (en) 2012-02-29 2015-02-05 Aicuris Gmbh & Co. Kg Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents
US20150133461A1 (en) 2012-02-29 2015-05-14 Aicuris Gmbh & Co. Kg Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
US9512085B2 (en) 2012-02-29 2016-12-06 Aicuris Gmbh & Co. Kg Salts of a dihydroquinazoline derivative
US9637459B2 (en) 2012-02-29 2017-05-02 Aicuris Gmbh & Co Kg. Sodium and calcium salts of dihydroquinazoline derivative and use thereof as antiviral agents
US20170362186A1 (en) 2012-02-29 2017-12-21 Aicuris Gmbh & Co. Kg Salts of a dihydroquinazoline derivative
US20160145216A1 (en) 2013-06-19 2016-05-26 Aicuris Anti-Infective Cures Gmbh Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration

Non-Patent Citations (49)

* Cited by examiner, † Cited by third party
Title
AiCuris Press Release, "AiCuris Drug Letermovir (AIC246) meets primary efficacy endpoints in phase 2 for human cytomegalovirus (HCMV) prophylaxis in human blood precursor cell recipients," Feb. 14, 2012, 3 pages.
Cleator, G. M et al., The Herpesviridae in, Principles and Practice of Clinical Virology 23-26 (Arie J. Zuckerman et al., eds., 5th ed., 2004).
Condit, R.C., Principles of Virology in, Fields' Virology 25-57 (David M. Knipe et al., eds., 5th ed., 2007).
Database Crossfire Beilstein 'Online!, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt Am Main, DE; BRN 360648; Beilstein Reference 4-22-00-05106; XP002213431 (2003).
Database Crossfire Beilstein 'Online!, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt Am Main, DE; BRN 75129-34-9; XP002213430; (CAS Registry No. 75129-34-9) (2003).
Desai et al., "Synthesis and anti-HIV activity of some non-nucleoside 2,3-disubstituted quinazoline derivatives (Part-V)," Indian J. Exp. Biol. (1998) 36(12):11280-1283 (abstract).
Desai et al., "Synthesis of substituted quinazolone derivatives as potential anti-HIV agents (Part III)," Farmaco (1996) 51(5):361-366 (abstract).
English language machine translation of DE4320347A1 published Dec. 22, 1994 to Boehringer Mannheim GmbH.
English language machine translation of WO2001002350A2 published Jan. 11, 2001 to Bayer AG.
Examiner's search strategy and results in U.S. Pat. No. 7,196,086, dated Nov. 20, 2005 (20 pages).
Examiner's search strategy and results, dated Nov. 30, 2005 (20 pages).
Freeman, R.B. et al., "Risk Factors for Cytomegalovirus Viremia and Disease Developing after Prophylaxis in High-Risk Solid Organ Transplant Recipients," Transplantation, 78(12):1765-1773 (Dec. 2004).
Gold, D. et al., "Acyclovir Prophylaxis for Herpes Simplex Virus Infection," Antimicrobial Agents and Chemotherapy, 31(3)1361-367 (1987).
Gribaudo, G., Riera, L., Lembo, D., De Andrea, M., Johnson, L., Landolfo, S., "The anticytomegaloviral activity of raltitrexed is abrogated in quiescent mouse fibroblasts that overexpress the thymidylate synthase," Virus Research, 73: 57-65 (2001). DOI:10.1016/S0168-1702(00)00223-9.
Griesser, Chapter 8, The Importance of Solvates (pp. 211-230), in the text, Polymorphism in the Pharmaceutical Industry, Hilfiker, 2006.
Griffiths, P.D., Cytomegalovirus in, Principles and Practice of Clinical Virology 85-122 (A.J. Zuckerman et al., eds, 5th ed., 2001).
Hart, G. et al., "Prophylaxis for CMV should now replace preemptive therapy in solid organ transplantation," Reviews in Medical Virology, 11, 73-81 (2001).
Lee et al., "3,4-Dihydroquinoline derivatives as novel selective T-type Ca2+ channel blockers", Biorg. & Med. Chem. Letters, 14 (2004), pp. 3379-3384.
Lischka et al., "Antiviral strategies to combat cytomegalovirus infections in transplant recipients," Current Opinion in Pharmacology, (2008) 8:1-8.
Madhavan Nair, P. et al., "Kinetic Studies In Ester Hydrolysis," Indian Academy of Sciences, pp. 187-196, (Year: 1950). *
Martinez, A., Gil, C., Castro, A., Bruno, A., Pérez, C., Prieto, C., Otero, J., "Benzothiadiazine dioxide human cytomegalovirus inhibitors: synthesis and antiviral evaluation of main heterocycle modified derivatives," Antiviral Chem. Chemo., 14: 107-114 (2003).
Marty et al.; The Lancet, vol. 11, Apr. 2011 pp. 284-292.
Misra, V. S., Varshneya, M., "Search for New Antiviral Agents. Part I. Synthesis of Aryl Sulfamoyl Benzamido Alkyl/Aralkyl Esters", J. Indian Chem. Soc., 51(II):963-964 (Nov. 1974).
Muller et al., "Facilitating the Design of Fluorinated Drugs", Chemistry & Biology, vol. 16, Nov. 25, 2009, pp. 1130-1133.
Muller et al., "Fluorine in Pharmaceuticals: Looking Beyond Intuition", Science, vol. 317, Sep. 28, 2007, pp. 1880-1886.
Mutimer, D., "CMV infection of transplant recipients," Journal of Hepatology, 25:259-269 (1996).
Nowlin, D.M. et al., Expression of a Human Cytomegalovirus Receptor Correlates with Infectibility of Cells, Journal of Virology, 65(6): 3114-3121 (1991).
Patani et al., "Bioisosterism: A Rational Approach in Drug Design", Chem. Rev., 1996; 96:3147-3176.
Pellett, P.E. et al., The Family Herpesviridae: A Brief Introduction in, Fields' Virology ; 2479-2499, (David M. Knipe et al., eds., 5th ed., 2007).
Saito, et al., "A Facile and Efficient Carbodiimide-Mediated Synthesis of Dihydroquinazolines via a Tandem Nucleophilic Addition-Intramolecular Hetero Conjugate Addition Annulation Strategy," Tet. Letts., 37(2): 209-212 (1996). DOI:10.1016/0040-4039(95)02130-2.
Schmidt, N.J. et al., Plaque Reduction Neutralization Test for Human Cytomegalovirus Based upon Enhanced Uptake of Neutral Red by Virus-Infected Cells, Journal of Clinical Microbiology, 4(1): 61-66 (1976).
Search Report from Ecuadorian Patent Application No. SP 05-6138, received Dec. 20, 2010, 1 page.
T. Goldner, 85 Journal of Virology, 10884 (2011).
Tan, "CMV prophylaxis—to do or not to do, that is the question," Nephrol. Dial. Transplant (2006) 21:1757-1761.
Tykwinski, "Evolution in the Palladium-Catalyzed Cross-Coupling of sp- and sp2-Hybridized Carbon Atoms," Angew. Chem. Int. Ed. (2003) 42:1566-1568.
US Food and Drug Administration Publication: Development of New Stereoisomeric Drugs. 1992.
Vippagunta et al., "Crystalline solids", Advanced Drug Delivery Review, vol. 48 (2001), pp. 3-26.
Viral Defense Found., Mission, http://www.viraldefense.org/mission.htm, downloaded Oct. 20, 2008.
Visiting Nurse Assns. of America, "Introduction to Viruses," downloaded from http://www.vnaa.org/vnaa/gen/Germ.sub.-Protection.sub.--Center.sub.-Col- d.sub.--and.sub.-Flu.sub.-Resources, downloaded Oct. 22, 2008.
Vulpetti et al., "Fluorine local environment: from screening to drug design", Durg Discovery Today, vol. 17, Nos. 15/16, Aug. 2012, pp. 890-897.
Waknine, "FDA Approves Longer Valganciclovir CMV Prophylaxis for Kidney Transplant Patients," WebMD Professional (Aug. 11, 2010) 2 pages.
Wang et al., Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001-2011), Chem. Rev., vol. 114, 2014, pp. 2432-2506.
Wang et al., Tet. Letts. (1997) 38(50):8651-8654. DOI:10.1016/S0040-4039(97)10377-X.
Whitley, R.J. et al., "Herpes Simplex Viruses Clinical," Infectious Diseases, 26:541-555 (1998).
Wikipedia, "Maribavir," updated Feb. 10, 2009, http://en.wikipedia.org/wiki/Maribavir, downloaded Mar. 10, 2009.
Winston, D.J. et al., "Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients," The Lancet, vol. 346, 69-74 (1995).
Wong, "Cytomegalovirus Prophylaxis in Renal Transplant Patients," The Hong Kong Medical Diary (2006) 11 (5):14-15.
Xin et al., "A practical and efficient intramolecular Michael addition of ureas to α,β-unsaturated esters," Tetrahedron Lett. (2000) 41(8):1147-1150.
Zimmermann et al., "Letermovir (AIC246)—A Novel Drug Under Development for Prevention and Treatment of Cytomegalovirus Infections Acting via a Novel Mechanism of Action", European Infectious Disease (2011) 5(2):112-114.

Also Published As

Publication number Publication date
HUS1800028I1 (en) 2018-07-30
US7196086B2 (en) 2007-03-27
EP1622880B1 (en) 2007-02-28
RU2360912C2 (en) 2009-07-10
TWI335912B (en) 2011-01-11
BRPI0410029B1 (en) 2019-12-31
CN1784390A (en) 2006-06-07
NO2018022I1 (en) 2018-07-04
EG25273A (en) 2011-12-04
CY2018019I1 (en) 2018-12-12
MA27794A1 (en) 2006-03-01
UA82519C2 (en) 2008-04-25
NO20055649L (en) 2006-01-31
HUS1800018I1 (en) 2018-05-28
NO20055649D0 (en) 2005-11-30
NZ543317A (en) 2008-05-30
MY144616A (en) 2011-10-14
PT1622880E (en) 2007-06-04
WO2004096778A1 (en) 2004-11-11
AR044078A1 (en) 2005-08-24
BRPI0410029B8 (en) 2021-06-15
FR18C1029I1 (en) 2018-08-17
NO333265B3 (en) 2019-06-03
JP4733631B2 (en) 2011-07-27
EP1622880A1 (en) 2006-02-08
JP2006525249A (en) 2006-11-09
BRPI0410029A (en) 2006-04-25
US8513255B2 (en) 2013-08-20
ATE355280T1 (en) 2006-03-15
PE20050145A1 (en) 2005-05-22
PL1622880T6 (en) 2018-08-31
KR20060009883A (en) 2006-02-01
KR100927063B1 (en) 2009-11-13
DK1622880T3 (en) 2007-06-25
DK1622880T6 (en) 2018-06-18
CN100393706C (en) 2008-06-11
DE10319612A1 (en) 2004-11-18
FR18C1029I2 (en) 2020-07-17
AU2004233978A1 (en) 2004-11-11
CY2018019I2 (en) 2018-12-12
CA2524069C (en) 2011-11-08
EP1622880B3 (en) 2018-05-23
ES2284007T3 (en) 2007-11-01
HN2004000146A (en) 2008-06-24
UY28294A1 (en) 2004-11-30
USRE46791E1 (en) 2018-04-17
US20050065160A1 (en) 2005-03-24
DE502004003052D1 (en) 2007-04-12
CO5700764A2 (en) 2006-11-30
AU2004233978B2 (en) 2010-02-11
NL300933I2 (en) 2018-04-26
US20070191387A1 (en) 2007-08-16
NO333265B1 (en) 2013-04-22
CL2004000930A1 (en) 2005-03-18
ECSP056138A (en) 2006-04-19
CY1106476T1 (en) 2012-01-25
CA2524069A1 (en) 2004-11-11
MXPA05011707A (en) 2006-02-13
HK1092463A1 (en) 2007-02-09
PL1622880T3 (en) 2007-08-31
SI1622880T1 (en) 2007-08-31
ES2284007T7 (en) 2018-06-20
TW200510343A (en) 2005-03-16
IL171513A (en) 2011-11-30
ZA200508710B (en) 2006-12-27
RU2005137276A (en) 2006-07-27

Similar Documents

Publication Publication Date Title
USRE49698E1 (en) Substituted dihydroquinazolines
US8198282B2 (en) Substituted azaquinazolines having an antiviral action
US7919489B2 (en) Heterocyclyamide-substituted imidazoles
US8343981B2 (en) Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents
US7960387B2 (en) 2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses
US8314113B2 (en) Substituted dihydroquinazolines II
US7709491B2 (en) Substituted quinazolines as antiviral agents, especially against cytomegaloviruses
US8410090B2 (en) Heterocyclylamide-substituted thiazoles, pyrroles and thiophenes

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: AIC246 GMBH & CO. KG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AICURIS ANTI-INFECTIVE CURES GMBH;REEL/FRAME:057371/0159

Effective date: 20210209

AS Assignment

Owner name: AIC246 AG & CO. KG, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:AIC246 GMBH & CO. KG;REEL/FRAME:057447/0605

Effective date: 20210723